Mäntylä R, Männistö PT, Vuorela A, Sundberg S, Ottoila P. Impairment of captopril bioavailability by concomitant food and antacid intake. Int J Clin Pharmacol Ther Toxicol (1984) 22, 626–9.
Singhvi SM, McKinstry DN, Shaw JM, Willard DA, Migdalof BH. Effect of food on the bioavailability of captopril in healthy subjects. J Clin Pharmacol (1982) 22, 135–40.
Öhman KP, Kågedal B, Larsson R, Karlberg BE. Pharmacokinetics of captopril and its effects on blood pressure during acute and chronic administration and in relation to food intake. J Cardiovasc Pharmacol (1985) 7 (Suppl 1), S20–S24.
Müller H-M, Overlack A, Heck I, Kolloch R, Stumpe KO. The influence of food intake on pharmacodynamics and plasma concentration of captopril. J Hypertens (1985) 3 (Suppl 2), S135–S136.
Salvetti A, Pedrinelli R, Magagna A, Abdel-Haq B, Graziadei L, Taddei S, Stornello M. Influence of food on acute and chronic effects of captopril in essential hypertensive patients. J Cardiovasc Pharmacol (1985) 7 (Suppl 1), S25–S29.
Mojaverian P, Rocci ML, Vlasses PH, Hoholick C, Clementi RA, Ferguson RK. Effect of food on the bioavailability of lisinopril, a nonsulfhydryl angiotensin-converting enzyme inhibitor. J Pharm Sci (1986) 75, 395–7.
Swanson BN, Vlasses PH, Ferguson RK, Bergquist PA, Till AE, Irvin JD, Harris K. Influence of food on the bioavailability of enalapril. J Pharm Sci (1984) 73, 1655–7.
Massarella JW, DeFeo TM, Brown AN, Lin A, Wills RJ. The influence of food on the pharmacokinetics and ACE inhibition of cilazapril. Br J Clin Pharmacol (1989) 27, 205S–209S.
Ferry JJ, Horvath AM, Sedman AJ, Latts JR, Colburn WA. Influence of food on the pharmacokinetics of quinapril and its active diacid metabolite, CI-928. J Clin Pharmacol (1987) 27, 397–9.
Grass P, Gerbeau C, Kutz K. Spirapril: pharmacokinetic properties and drug interactions. Blood Pressure (1994) 3 (Suppl 2), 7–13.
Stimpel M, Cawello W. Pharmacokinetics and ACE-inhibition of the new ACE-inhibitor moexipril: is coadministration with food of clinical relevance? Hypertension (1995) 25, 1384.
Lecocq B, Funck-Brentano C, Lecocq V, Ferry A, Gardin M-E, Devissaguet M, Jaillon P. Influence of food on the pharmacokinetics of perindopril and the time course of angiotensin-converting enzyme inhibition in serum. Clin Pharmacol Ther (1990) 47, 397–402.
Zaidenstein R, Soback S, Gips M, Avni B, Dishi V, Weissgarten Y, Golik A, Scapa E. Effect of grapefruit juice on the pharmacokinetics of losartan and its active metabolite E3174 in healthy volunteers. Ther Drug Monit (2001) 23, 369–73.
Mattila MJ, Aranko K, Seppala T. Acute effects of buspirone and alcohol on psychomotor skills. J Clin Psychiatry (1982) 43, 56–60.
Seppälä T, Aranko K, Mattila MJ, Shrotriya RC. Effects of alcohol on buspirone and lorazepam actions. Clin Pharmacol Ther (1982) 32, 201–7.
Rush CR, Griffiths RR. Acute participant-rated and behavioral effects of alprazolam and buspirone, alone and in combination with ethanol, in normal volunteers. Exp Clin Psychopharmacol (1997) 5, 28–38.
Erwin CW, Linnoila M, Hartwell J, Erwin A, Guthrie S. Effects of buspirone and diazepam, alone and in combination with alcohol, on skilled performance and evoked potentials. J Clin Psychopharmacol (1986) 6, 199–209.
Evans SM, Levin FR. The effects of alprazolam and buspirone in light and moderate female social drinkers. Behav Pharmacol (2002) 13, 427–39.
Lewis W, Schwartz L. An occupational agent (N-butyraldoxime) causing reaction to alcohol. Med Ann Dist Columbia (1956) 25, 485–90.
DeMaster EG, Redfern B, Shirota FN, Crankshaw DL, Nagasawa HT. Metabolic activation of n-butyraldoxime by rat liver microsomal cytochrome P450. A requirement for the inhibition of aldehyde dehydrogenase. Biochem Pharmacol (1993) 46, 117–23.
Franks HM, Hagedorn H, Hensley VR, Hensley WJ, Starmer GA. The effect of caffeine on human performance, alone and in combination with alcohol. Psychopharmacologia (1975) 45, 177–81.
Nuotto E, Mattila MJ, Seppälä T, Konno K. Coffee and caffeine and alcohol effects on psychomotor function. Clin Pharmacol Ther (1982) 31, 68–76.
Newman HW, Newman EJ. Failure of dexedrine and caffeine as practical antagonists of the depressant effect of ethyl alcohol in man. Q J Stud Alcohol (1956) 17, 406–10.
Lee DJ, Lowe G. Interaction of alcohol and caffeine in a perceptual-motor task. IRCS Med Sci (1980) 8, 420.
Oborne DJ, Rogers Y. Interactions of alcohol and caffeine on human reaction time. Aviat Space Environ Med (1983) 54, 528–34.
Azcona O, Barbanoj MJ, Torrent J, Jané F. Evaluation of the central effects of alcohol and caffeine interaction. Br J Clin Pharmacol (1995) 40, 393–400.
Marczinski CA, Fillmore MT. Dissociative antagonistic effects of caffeine on alcohol-induced impairment of behavioral control. Exp Clin Psychopharmacol (2003) 11, 228–36.
Mackay M, Tiplady B, Scholey AB. Interactions between alcohol and caffeine in relation to psychomotor speed and accuracy. Hum Psychopharmacol (2002) 17, 151–6.
Drake CL, Roehrs T, Turner L, Scofield HM, Roth T. Caffeine reversal of ethanol effects on the multiple sleep latency test, memory, and psychomotor performance. Neuropsychopharmacology (2003) 28, 371–8.
Liguori A, Robinson JH. Caffeine antagonism of alcohol-induced driving impairment. Drug Alcohol Depend (2001) 63, 123–9.
Caley MJ, Clarke RA. Cardiac arrhythmia after mushroom ingestion. BMJ (1977) 2, 1633.
Reynolds WA, Lowe FH. Mushrooms and a toxic reaction to alcohol: report of four cases. N Engl J Med (1965) 272, 630–1.
Wildervanck LS. Alcohol en de kale inktzwam. Ned Tijdschr Geneeskd (1978) 122, 913–14.
Buck RW. Mushroom toxins—a brief review of the literature. N Engl J Med (1961) 265, 681–6.
Marty H. Von Pilzen und Schnäpsen. Schweiz Med Wochenschr (1998) 128, 598.
Flammer R. Brechdurchfälle als Leitsymptom – Pilze und Alkohol. Emesis and diarrhea – mushrooms and alcohol. Schweiz Rundsch Med Prax (1985) 74, 992–6.
Oteo Revuelta JA, Grandival García R, Olarte Arce A. Reaccíon disulfiram-like por ingesta de hongos [Disulfiram-like reaction caused by mushroom ingestion]. Rev Clin Esp (1989) 184, 394–5.
Broadhurst-Zingrich L. Ink caps and alcohol. BMJ (1978) 1, 511.
Budmiger H, Kocher F. Hexenröhrling (Boletus luridus) mit Alkohol: ein kasuistischer beitrag. Schweiz Med Wochenschr (1982) 112, 1179–81.
Cochran KW, Cochran MW. Clitocybe clavipes: antabuse-like reaction to alcohol. Mycologia (1978) 70, 1124–6.
Oso BA. Mushrooms and the Yoruba people of Nigeria. Mycologia (1975) 67, 311–19.
Simandl J, Franc J. Isolace tetraethylthiuramdisulfidu z hníku inko ustového (Coprinus atramentarius). Chem Listy (1956) 50, 1862–3.
Vanhaelen M, Vanhaelen-Fastré R, Hoyois J, Mardens Y. Reinvestigation of disulfiram-like biological activity of Coprinus atramentarius (Bull. ex Fr.) Fr. extracts. J Pharm Sci (1976) 65, 1774–6.
Wier JK, Tyler VE. An investigation of Coprinus atramentarius for the presence of disulfiram. J Am Pharm Assoc (1960) 49, 426–9.
Hatfield GM, Schaumberg JP. Isolation and structural studies of coprine, the disulfiram-like constituent of Coprinus atramentarius. Lloydia (1975) 38, 489–96.
Lindberg P, Bergman R, Wickberg B. Isolation and structure of coprine, the in vivo aldehyde dehydrogenase inhibitor in Coprinus atramentarius; syntheses of coprine and related cyclopropanone derivatives. J Chem Soc (1977) (6) 684–91.
Fujiyama Y, Naitoh M, Nakamura M, Minezaki K, Shigeta Y, Okubo M. [Mushroom poisoning whose symptoms were relevant to the amount of alcohol taken]. Nippon Naika Gakkai Zasshi (2002) 91, 2189–91.
Radford AP. Ink caps and mushrooms. BMJ (1978) 1, 112.
Miller DS, Stirling JL, Yudkin J. Effect of ingestion of milk on concentrations of blood alcohol. Nature (1966) 212, 1051.
Fraser AG, Rosalki SB, Gamble GD, Pounder RE. Inter-individual and intra-individual variability of ethanol concentration-time profiles: comparison of ethanol ingestion before or after an evening meal. Br J Clin Pharmacol (1995) 40, 387–92.
Jones AW, Jönsson KÅ. Food-induced lowering of blood-ethanol profiles and increased rate of elimination immediately after a meal. J Forensic Sci (1994) 39, 1084–93.
Jones AW, Jönsson KÅ, Kechagias S. Effect of high-fat, high-protein, and high-carbohydrate meals on the pharmacokinetics of a small dose of ethanol. Br J Clin Pharmacol (1997) 44, 521–6.
Ramchandani VA, Kwo PY, Li T-K. Effect of food and food composition on alcohol elimination rates in healthy men and women. J Clin Pharmacol (2001) 41, 1345–50.
Helander A, Some M. Dietary serotonin and alcohol combined may provoke adverse physiological symptoms due to 5-hydroxytryptophol. Life Sci (2000) 67, 799–806.
Benton D, Nabb S. Breakfasts that release glucose at different speeds interact with previous alcohol intake to influence cognition and mood before and after lunch. Behav Neurosci (2004) 118, 936–43.
Lee FC, Ko JH, Park KJ, Lee JS. Effect of Panax ginseng on blood alcohol clearance in man. Clin Exp Pharmacol Physiol (1987) 14, 543–6.
Choi CW, Lee SI, Huh K. Effect of ginseng on the hepatic alcohol metabolizing enzyme system activity in chronic alcohol-treated mice. Korean J Pharmacol (1984) 20, 13–21.
Carai MAM, Agabio R, Bombardelli E, Bourov I, Gessa GL, Lobina C, Morazzoni P, Pani M, Reali R, Vacca G, Colombo G. Potential use of medicinal plants in the treatment of alcoholism. Fitoterapia (2000) 71 (Suppl 1), S38–S42.
Foo H, Lemon J. Acute effects of kava, alone or in combination with alcohol, on subjective measures of impairment and intoxication and on cognitive performance. Drug Alcohol Rev (1997) 16, 147–55.
Herberg K-W. Zum Einfluß von Kava-Spezialextrakt WS 1490 in Kombination mit Ethylalkohol auf sicherheitsrelevante Leistungsparameter. The influence of kava-special extract WS 1490 on safety-relevant performance alone and in combination with ethyl alcohol. Blutalkohol (1993) 30, 96–105.
Chauhan BL, Kulkarni RD. Alcohol hangover and Liv.52. Eur J Clin Pharmacol (1991) 40, 187–8.
Chauhan BL, Kulkarni RD. Effect of Liv.52, a herbal preparation, on absorption and metabolism of ethanol in humans. Eur J Clin Pharmacol (1991) 40, 189–91.
Hobbes J, Boutagy J, Shenfield GM. Interactions between ethanol and oral contraceptive steroids. Clin Pharmacol Ther (1985) 38, 371–80.
Jones MK, Jones BM. Ethanol metabolism in women taking oral contraceptives. Alcohol Clin Exp Res (1984) 8, 24–8.
Zeiner AR, Kegg PS. Menstrual cycle and oral contraceptive effects on alcohol pharmacokinetics in caucasian females. Curr Alcohol (1981) 8, 47–56.
Sarkola T, Ahola L, von der Pahlen B, Eriksson CJP. Lack of effect of alcohol on ethinylestradiol in premenopausal women. Contraception (2001) 63, 19–23.
Lee A, Chui PT, Aun CST, Gin T, Lau ASC. Possible interaction between sevoflurane and aloe vera. Ann Pharmacother (2004) 38, 1651–4.
Anon. Piper methysticum (kava kava). Altern Med Rev (1998) 3, 458–60.3. Pepping J. Kava: Piper methysticum. Am J Health-Syst Pharm (1999) 56, 957–8 and 960
Larkin, M. Surgery patients at risk for herb–anaesthesia interactions. Lancet (1999) 354, 1362.
Cheng B, Hung CT, Chiu W. Herbal medicine and anaesthesia. Hong Kong Med J (2002) 8, 123–30.
Leak JA. Perioperative considerations in the management of the patient taking herbal medicines. Curr Opin Anaesthesiol (2000) 13, 321–5.
Lyons TR. Herbal medicines and possible anesthesia interactions. AANA J (2002) 70, 47–51.
Klepser TB, Klepser ME. Unsafe and potentially safe herbal therapies. Am J Health-Syst Pharm (1999) 56, 125–38.
Miller LG. Herbal medicinals. Selected clinical considerations focusing on known or potential drug-herb interactions. Arch Intern Med (1998) 158, 2200–11.
Irefin S, Sprung J. A possible cause of cardiovascular collapse during anesthesia: long-term use of St John’s wort. J Clin Anesth (2000) 12, 498–9.
Hiller K-O, Zetler G. Neuropharmacological studies on ethanol extracts of Valeriana officinalis L.; behavioural and anticonvulsant properties. Phytother Res (1996) 10,145–51.
Stempak D, Gammon J, Halton J, Champagne M, Koren G, Baruchel S. Modulation of celecoxib pharmacokinetics by food in pediatric patients. Clin Pharmacol Ther (2005) 77, 226–8.
Poli A, Moreno RA, Ribiero W, Dias HB, Moreno H, Muscara MN, De Nucci G. Influence of gastric acid secretion blockade and food intake on the bioavailability of a potassium diclofenac suspension in healthy male volunteers. Int J Clin Pharmacol Ther (1996) 34, 76–9.
Sioufi A, Stierlin H, Schweizer A, Botta L, Degen PH, Theobald W, Brechbühler S. Recent findings concerning clinically relevant pharmacokinetics of diclofenac sodium. In: Voltarol — New Findings, ed Kass E. Proc Int Symp Voltarol, Paris June 22nd, 1981. 15th Int Congress of Rheumatology. p 19–30.
Troy S, Sanda M, Dressler D, Chiang S, Latts J. The effect of food and antacid on etodolac bioavailability. Clin Pharmacol Ther (1990) 47, 192.
McEwen J, De Luca M, Casini A, Gich I, Barbanoj MJ, Tost D, Artigas R, Mauleón D. The effect of food and an antacid on the bioavailability of dexketoprofen trometamol. J Clin Pharmacol (1998) 38 (Suppl), 41S–45S.
Pargal A, Kelkar MG, Nayak PJ. The effect of food on the bioavailability of ibuprofen and flurbiprofen from sustained release formulation. Biopharm Drug Dispos (1996) 17, 511–19.
Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther (2006) 79, 125–33.
Levine MA, Walker SE, Paton TW. The effect of food or sucralfate on the bioavailability of S(+) and R(-) enantiomers of ibuprofen. J Clin Pharmacol (1992) 32, 1110–14.
Siemon D, de Vries JX, Stötzer F, Walter-Sack I, Dietl R. Fasting and postprandial disposition of R(-)- and S(+)-ibuprofen following oral administration of racemic drug in healthy individuals. Eur J Med Res (1997) 2, 215–19.
Klueglich M, Ring A, Scheuerer S, Trommeshauser D, Schuijt C, Liepold B, Berndl G. Ibuprofen extrudate, a novel, rapidly dissolving ibuprofen formulation: relative bioavailability compared to ibuprofen lysinate and regular ibuprofen, and food effect on all formulations. J Clin Pharmacol (2005) 45, 1055–61.
Caillé G, du Souich P, Besner JG, Gervais P, Vèzina M. Effects of food and sucralfate on the pharmacokinetics of naproxen and ketoprofen in humans. Am J Med (1989) 86 (Suppl 6A) 38–44. Correction. ibid. (1990) 89, 838.
Bannwarth B, Lapicque F, Netter P, Monot C, Tamisier JN, Thomas P, Royer RJ. The effect of food on the systemic availability of ketoprofen. Eur J Clin Pharmacol (1988) 33, 643–5.
Le Liboux A, Teule M, Frydman A, Oosterhuis B, Jonkman JHG. Effect of diet on the single- and multiple-dose pharmacokinetics of sustained-release ketoprofen. Eur J Clin Pharmacol (1994) 47, 361–6.
Eshra AG, Etman MA, Naggar VF. Effect of milk and food on the bioavailability of ketoprofen in man. Int J Pharmaceutics (1988) 44, 9–14.
Mroszczak E, Yee JP, Bynum L. Absorption of naproxen controlled-release tablets in fasting and postprandial volunteers. J Clin Pharmacol (1988) 28, 1128–31.
Palazzini E, Cristofori M, Babbini M. Bioavailability of a new controlled-release oral naproxen formulation given with and without food. Int J Clin Pharmacol Res (1992) 12, 179–84.
Forbes JA, Sandberg RÅ, Bood-Björklund L. The effect of food on bromfenac, naproxen sodium, and acetaminophen in postoperative pain after orthopedic surgery. Pharmacotherapy (1998) 18, 492–503.
Marzo A, Dal Bo L, Wool C, Cerutti R. Bioavailability, food effect and tolerability of S-naproxen betainate sodium salt monohydrate in steady state. Arzneimittelforschung (1998) 48, 935–40.
Emori HW, Paulus H, Bluestone R, Champion GD, Pearson C. Indomethacin serum concentrations in man. Effects of dosage, food, and antacid. Ann Rheum Dis (1976) 35, 333–8.
von Schrader HW, Buscher G, Dierdorf D, Mügge H, Wolf D. Nabumetone — a novel anti-inflammatory drug: the influence of food, milk, antacids, and analgesics on bioavailability of single oral doses. Int J Clin Pharmacol Ther Toxicol (1983) 21, 311–21.
Ishizaki T, Nomura T, Abe T. Pharmacokinetics of piroxicam, a new nonsteroidal anti-inflammatory agent, under fasting and postprandial states in man. J Pharmacokinet Biopharm (1979) 7, 369–81.
Tilstone WJ, Lawson DH, Omara F, Cunningham F. The steady-state pharmacokinetics of piroxicam: effect of food and iron. Eur J Rheumatol Inflamm (1981) 4, 309–13.
Day RO, Lam S, Paull P, Wade D. Effect of food and various antacids on the absorption of tenoxicam. Br J Clin Pharmacol (1987) 24, 323–8.
Busch U, Heinzel G, Narjes H. Effect of food on pharmacokinetics of meloxicam, a new non steroidal anti-inflammatory drug (NSAID). Agents Actions (1991) 32, 52–3.
Meisel C, Johne A, Roots I. Fatal intracerebral mass bleeding associated with Ginkgo biloba and ibuprofen. Atherosclerosis (2003) 167, 367.
Hoffman T. Ginko, Vioxx and excessive bleeding – possible drug-herb interactions: case report. Hawaii Med J (2001) 60, 290.
Greenblatt DJ, von Moltke LL, Luo Y, Perloff ES, Horan KA, Bruce A, Reynolds RC, Harmatz JS, Avula B, Khan IA, Goldman P. Ginkgo biloba does not alter clearance of flurbiprofen, a cytochrome P450-2C9 substrate. J Clin Pharmacol (2006) 46, 214–21.
Mohutsky MA, Anderson GD, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther (2006) 13, 24–31.
Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology (1996) 46, 1775–6.
Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet (1998) 352, 36.
Gilbert GJ. Ginkgo biloba. Neurology (1997) 48, 1137.
Benjamin J, Muir T, Briggs K, Pentland B. A case of cerebral haemorrhage – can Ginkgo biloba be implicated? Postgrad Med J (2001) 77, 112–13.
Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg (2001) 67, 33–5.
Kharasch ED, Walker A, Hoffer C, Sheffels P. Intravenous and oral alfentanil as in vivo probes for hepatic and first-pass cytochrome P450 3A activity: non-invasive assessment by use of papillary miosis. Clin Pharmacol Ther (2004) 76, 452–66.
Kharasch ED, Whittington D, Hoffer C. Influence of hepatic and intestinal cytochrome P4503A activity on the acute disposition and effects of oral transmucosal fentanyl citrate. Anesthesiology (2004) 101, 729–37.
Benmebarek M, Devaud C, Gex-Fabry M, Powell Golay K, Brogli C, Baumann P, Gravier B, Eap CB. Effects of grapefruit juice on the pharmacokinetics of the enantiomers of methadone. Clin Pharmacol Ther (2004) 76, 55–63.
Kharasch ED, Hoffer C, Whittington D, Sheffels P. Role of hepatic and intestinal cytochrome P450 3A and 2B6 in the metabolism, disposition, and miotic effects of methadone. Clin Pharmacol Ther (2004) 76, 250–69.
Van Thuyne W, Van Eenoo P, Delbeke FT. Urinary concentrations of morphine after the administration of herbal teas containing Papaveris fructus in relation to doping analysis. J Chromatogr B Analyt Technol Biomed Life Sci (2003) 785, 245–51.
Eic-Höchli D, Oppliger R, Powell Golay K, Baumann P, Eap CB. Methadone maintenance treatment and St John’s wort. Pharmacopsychiatry (2003) 36, 35–7.
Kumar NB, Allen K, Bel H. Perioperative herbal supplement use in cancer patients: potential implications and recommendations for presurgical screening. Cancer Control (2005) 12, 149–57.
Robertson DRC, Higginson I, Macklin BS, Renwick AG, Waller DG, George CF. The influence of protein containing meals on the pharmacokinetics of levodopa in healthy volunteers. Br J Clin Pharmacol (1991) 31, 413–17.
Wessels JC, Koeleman HA, Boneschans B, Steyn HS. The influence of different types of breakfast on the absorption of paracetamol among members of an ethnic group. Int J Clin Pharmacol Ther Toxicol (1992) 30, 208–13.
Rostami-Hodjegan A, Shiran MR, Ayesh R, Grattan TJ, Burnett I, Darby-Dowman A, Tucker GT. A new rapidly absorbed paracetamol tablet containing sodium bicarbonate. I. A four-way crossover study to compare the concentration-time profile of paracetamol from the new paracetamol/sodium bicarbonate tablet and a conventional paracetamol tablet in fed and fasted volunteers. Drug Dev Ind Pharm (2002) 28, 523–31.
Walter-Sack IE, de Vries JX, Nickel B, Stenzhorn G, Weber E. The influence of different formula diets and different pharmaceutical formulations on the systemic availability of paracetamol, gallbladder size, and plasma glucose. Int J Clin Pharmacol Ther Toxicol (1989) 27, 544–50.
Holt S, Heading RC, Carter DC, Prescott LF, Tothill P. Effect of gel fibre on gastric emptying and absorption of glucose and paracetamol. Lancet (1979) 1, 636–9.
Forbes JA, Sandberg RA, Bood-Bjorklund L. The effect of food on bromfenac, naproxen sodium, and acetaminophen in postoperative pain after orthopedic surgery. Pharmacotherapy (1998) 18, 492–503.
Burnett I, Schachtel B, Sanner K, Bey M, Grattan T, Littlejohn S. Onset of analgesia of a paracetamol tablet containing sodium bicarbonate: a double-blind, placebo-controlled study in adult patients with acute sore throat. Clin Ther (2006) 28, 1273–8.
Prescott LF, Yoovathaworn K, Makarananda K, Saivises R, Sriwatanakul K. Impaired absorption of paracetamol in vegetarians. Br J Clin Pharmacol (1993) 36, 237–40.
Stillings M, Havlik I, Chetty M, Clinton C, Schall R, Moodley I, Muir N, Little S. Comparison of the pharmacokinetic profiles of soluble aspirin and solid paracetamol tablets in fed and fasted volunteers. Curr Med Res Opin (2000) 16, 115–24.
Whitcomb DC, Block GD. Association of acetaminophen hepatotoxicity with fasting and ethanol use. JAMA (1994) 272, 1845–50.
Schenker S, Speeg KV, Perez A, Finch J. The effects of food restriction in man on hepatic metabolism of acetaminophen. Clin Nutr (2001) 20, 145–50.
Pantuck EJ, Pantuck CB, Anderson KE, Wattenberg LW, Conney AH, Kappas A. Effect of brussels sprouts and cabbage on drug conjugation. Clin Pharmacol Ther (1984) 35, 161–9.
Chen L, Mohr SN, Yang CS. Decrease of plasma and urinary oxidative metabolites of acetaminophen after consumption of watercress by human volunteers. Clin Pharmacol Ther (1996) 60, 651–60.
Anderson KE, Schneider J, Pantuck EJ, Pantuck CB, Mudge GH, Welch RM, Conney AH, Kappas A. Acetaminophen metabolism in subjects fed charcoal-broiled beef. Clin Pharmacol Ther (1983) 34, 369–74.
Gwilt PR, Lear CL, Tempero MA, Birt DD, Grandjean AC, Ruddon RW, Nagel DL. The effect of garlic extract on human metabolism of acetaminophen. Cancer Epidemiol Biomarkers Prev (1994) 3, 155–60.
Kolawole JA, Maduenyi A. Effect of Zobo drink (Hibiscus sabdariffa water extract) on the pharmacokinetics of acetaminophen in human volunteers. Eur J Drug Metab Pharmacokinet (2004) 29, 25–9.
Qi J, Toyoshima A, Honda Y, Mineshita S. Pharmacokinetic study on acetaminophen: interaction with a Chinese medicine. J Med Dent Sci (1997) 44, 31–5.
Homeida M, Leahy W, Copeland S, Ali MMM, Harron DWG. Pharmacokinetic interaction between praziquantel and albendazole in Sudanese men. Ann Trop Med Parasitol (1994) 88, 551–9.
Nagy J, Schipper HG, Koopmans RP, Butter JJ, Van Boxtel CJ, Kager PA. Effect of grapefruit juice or cimetidine coadministration on albendazole bioavailability. Am J Trop Med Hyg (2002) 66, 260–3.
Feeley J, Heidemann H, Gerkens J, Roberts LJ, Branch RA. Sodium depletion enhances nephrotoxicity of amphotericin B. Lancet (1981) i, 1422–3.
Heidemann HT, Gerkens JF, Spickard WA, Jackson EK, Branch RA. Amphotericin B nephrotoxicity in humans decreased by salt repletion. Am J Med (1983) 75, 476–81.
Dixon R, Pozniak AL, Watt HM, Rolan P, Posner J. Single-dose and steady-state pharmacokinetics of a novel microfluidized suspension of atovaquone in human immunodeficiency virus-seropositive patients. Antimicrob Agents Chemother (1996) 40, 556–60.
Falloon J, Sargent S, Piscitelli SC, Bechtel C, LaFon SW, Sadler B, Walker RE, Kovacs JA, Polis MA, Davey RT, Lan HC, Masur H. Atovaquone suspension in HIV-infected volunteers: pharmacokinetics, pharmacodynamics, and TMP-SMX interaction study. Pharmacotherapy (1999) 19, 1050–6.
Freeman CD, Klutman NE, Lamp KC, Dall LH, Strayer AH. Relative bioavailability of atovaquone suspension when administered with an enteral nutrition supplement. Ann Pharmacother (1998) 32, 1004–7.
Rolan PE, Mercer AJ, Weatherley BC, Holdich T, Meire H, Peck RW, Ridout G, Posner J. Examination of some factors responsible for a food-induced increase in absorption of atovaquone. Br J Clin Pharmacol (1994) 37, 13–20.
Jaruratanasirikul S, Kleepkaew A. Influence of an acidic beverage (Coca-Cola) on absorption of itraconazole. Eur J Clin Pharmacol (1997) 52, 235–7.
Hardin J, Lange D, Heykants J, Ding C, Van de Velde V, Slusser C, Klausner M. The effect of co-administration of a cola beverage on the bioavailability of itraconazole in AIDS patients. Intersci Conf Antimicrob Agents Chemother (1995) 35, 6.
Lange D, Pavao JH, Wu J, Klausner M. Effect of cola beverage on the bioavailability of itraconazole in the presence of H 2 blockers. J Clin Pharmacol (1997) 37, 535–40.
Chin TWF, Loeb M, Fong IW. Effects of an acidic beverage (Coca-Cola) on absorption of ketoconazole. Antimicrob Agents Chemother (1995) 39, 1671–5.
Zimmermann T, Yeates RA, Laufen H, Pfaff G, Wildfeuer A. Influence of concomitant food intake on the oral absorption of two triazole antifungal agents, itraconazole and fluconazole. Eur J Clin Pharmacol (1994) 46, 147–150.
Wishart JM. The influence of food on the pharmacokinetics of itraconazole in patients with superficial fungal infection. J Am Acad Dermatol (1987) 17, 220–3.
Carver P, Welage L, Kauffman C. The effect of food and gastric pH on the oral bioavailability of itraconazole in HIV+ patients. Intersci Conf Antimicrob Agents Chemother (1996) 36, 6.
Barone JA, Koh JG, Bierman RH, Colaizzi JL, Swanson KA, Gaffar MC, Moskovitz BL, Mechlinski W, Van De Velde V. Food interaction and steady-state pharmacokinetics of itraconazole capsules in healthy male volunteers. Antimicrob Agents Chemother (1993) 37, 778–.
Barone JA, Moskovitz BL, Guarnieri J, Hassell AE, Colaizzi JL, Bierman RH, Jessen L. Food interaction and steady-state pharmacokinetics of itraconazole oral solution in healthy volunteers. Pharmacotherapy (1998) 18, 295–301.
Männistö PT, Mäntylä R, Nykänen S, Lamminsivu U, Ottoila P. Impairing effect of food on ketoconazole absorption. Antimicrob Agents Chemother (1982) 21, 730–33.
Lelawongs P, Barone JA, Colaizzi JL, Hsuan ATM, Mechlinski W, Legendre R, Guarnieri J. Effect of food and gastric acidity on absorption of orally administered ketoconazole. Clin Pharm (1988) 7, 228–35.
Daneshmend TK, Warnock DW, Ene MD, Johnson EM, Potten MR, Richardson MD, Williamson PJ. Influence of food on the pharmacokinetics of ketoconazole. Antimicrob Agents Chemother (1984) 25, 1–3.
Courtney R, Sansone A, Calzetta A, Martinho M, Laughlin. The effect of a nutritional supplement (Boost Plus) on the oral bioavailability of posaconazole. Intersci Conf Antimicrob Agents Chemother (2003) 43, 33.
Courtney R, Wexler D, Radwanski E, Lim J, Laughlin M. Effect of food on the relative bio-availability of two oral formulations of posaconazole in healthy adults. Br J Clin Pharmacol (2004) 57, 218–22.
Purkins L, Wood N, Kleinermans D, Greenhalgh K, Nichols D. Effect of food on the pharmacokinetics of multiple-dose oral voriconazole. Br J Clin Pharmacol (2003) 56 (Suppl 1) 17–23.
Penzak SR, Gubbins PO, Gurley BJ, Wang P-L, Saccente M. Grapefruit juice decreases the systemic availability of itraconazole capsules in healthy volunteers. Ther Drug Monit (1999) 21, 304–309.
Kawakami M, Suzuki K, Ishizuka T, Hidaka T, Matsuki Y, Nakumara H. Effect of grapefruit juice on pharmacokinetics of itraconazole in healthy subjects. Int J Clin Pharmacol Ther (1998) 36, 306–308.
Gubbins PO, McConnell SA, Gurley BJ, Fincher TK, Franks AM, Williams DK, Penzak SR, Saccente M. Influence of grapefruit juice on the systemic availability of itraconazole oral solution in healthy adult volunteers. Pharmacotherapy (2004) 24, 460–7.
Bindschedler M, et al. Comparative bioavailability of benflumetol after administration of single oral doses of co-artemether under fed and fasted conditions to healthy subjects. Cited in Lefèvre G, Thomsen MS. Clinical Pharmacokinetics of artemether and lumefantrine (Riamet®). Clin Drug Invest (1999) 18, 467–80.
Ezzet F, van Vugt M, Nosten F, Looareesuwan S, White NJ. Pharmacokinetics and pharmacodynamics of lumefantrine (Benflumetol) in acute falciparum malaria. Antimicrob Agents Chemother (2000) 44, 697–704.
van Agtmael MA, Gupta V, van der Wosten TH, Rutten JP, van Boxtel CJ. Grapefruit juice increases the bioavailability of artemether. Eur J Clin Pharmacol (1999) 55, 405–10.
van Agtmael MA, Gupta V, van der Graaf CAA, van Boxtel CJ. The effect of grapefruit juice on the time-dependent decline of artemether plasma levels in healthy subjects. Clin Pharmacol Ther (1999) 66, 408–14.
Vanapalli SR, Chen Y, Ellingrod VL, Kitzman D, Lee Y, Hohl RJ, Fleckenstein L. Orange juice decreases the oral bioavailability of ivermectin in healthy volunteers. Clin Pharmacol Ther (2003) 73, P94.
Castro N, Jung H, Medina R, González-Esquivel D, Lopez M, Sotelo J. Interaction between grapefruit juice and praziquantel in humans. Antimicrob Agents Chemother (2002) 46, 1614–16.
Ho PC, Chalcroft SC, Coville PF, Wanwimolruk S. Grapefruit juice has no effect on quinine pharmacokinetics. Eur J Clin Pharmacol (1999) 55, 393–8.
Libersa CC, Brique SA, Motte KB, Caron JF, Guédon-Moreau LM, Humbert L, Vincent A, Devos P, Lhermitte MA. Dramatic inhibition of amiodarone metabolism induced by grapefruit juice. Br J Clin Pharmacol (2000) 49, 373–8.
Munoz CE, Ito S, Bend JR, Tesoro A, Freeman D, Spence JD, Bailey DG. Propafenone interaction with CYP3A4 inhibitors in man. Clin Pharmacol Ther (1997) 61, 154.
Min DI, Ku Y-M, Geraets DR, Lee H-C. Effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of quinidine in healthy volunteers. J Clin Pharmacol (1996) 36, 469–76.
Damkier P, Hansen LL, Brøsen K. Effect of diclofenac, disulfiram, itraconazole, grapefruit juice and erythromycin on the pharmacokinetics of quinidine. Br J Clin Pharmacol (1999) 48, 829–38.
Zhu M, Nix DE, Adam RD, Childs JM, Peloquin CA. Pharmacokinetics of cycloserine under fasting conditions and with high-fat meal, orange juice, and antacids. Pharmacotherapy (2001) 21, 891–7.
Peloquin CA, Bulpitt AE, Jaresko GS, Jelliffe RW, Childs JM, Nix DE. Pharmacokinetics of ethambutol under fasting conditions, with food, and with antacids. Antimicrob Agents Chemother (1999) 43, 568–72.
Melander A, Danielson K, Hanson A, Jansson L, Rerup C, Scherstén B, Thulin T, Wåhlin E. Reduction of isoniazid bioavailability in normal men by concomitant intake of food. Acta Med Scand (1976) 200, 93–7.
Peloquin CA, Namdar S, Dodge AA, Nix DE. Pharmacokinetics of isoniazid under fasting conditions, with food, and with antacids. Int J Tuberc Lung Dis (1999) 3, 703–710.
Männisto P, Mäntylä R, Klinge R, Nykänen S, Koponen A, Lamminsivu U. Influence of various diets on the bioavailability of isoniazid. J Antimicrob Chemother (1982) 10, 427–34.
Smith CK, Durack DT. Isoniazid and reaction to cheese. Ann Intern Med (1978) 88, 520–1.
Uragoda CG, Lodha SC. Histamine intoxication in a tuberculous patient after ingestion of cheese. Tubercle (1979) 60, 59–61.
Lejonc JL, Gusmini D, Brochard P. Isoniazid and reaction to cheese. Ann Intern Med (1979) 91, 793.
Hauser MJ, Baier H. Interactions of isoniazid with foods. Drug Intell Clin Pharm (1982) 16, 617–18.
Toutoungi M, Carroll R, Dick P. Isoniazide (INH) and tyramine-rich food. Chest (1986) 89 (Suppl 6), 540S.
Carvalho ACC, Manfrin M, Gore RP, Capone S, Scalvini A, Armellini A, Giovine T, Carosi G, Matteelli A. Reaction to cheese during TB treatment. Thorax (2004) 59, 635.
Uragoda CG, Kottegoda SR. Adverse reactions to isoniazid on ingestion of fish with a high histamine content. Tubercle (1977) 58, 83–9.
Uragoda CG. Histamine poisoning in tuberculous patients after ingestion of tuna fish. Am Rev Respir Dis (1980) 121, 157–9.
Senanayake N, Vyravanathan S, Kanagasuriyam S. Cerebrovascular accident after a ‘skipjack’ reaction in a patient taking isoniazid. BMJ (1978) 2, 1127–8.
Senanayake N, Vyravanathan S. Histamine reactions due to ingestion of tuna fish (Thunus argentivittatus) in patients on antituberculosis therapy. Toxicon (1981) 19, 184–5.
Morinaga S, Kawasaki A, Hirata H, Suzuki S, Mizushima Y. Histamine poisoning after ingestion of spoiled raw tuna in a patient taking isoniazid. Intern Med (1997) 36, 198–200.
Uragoda CG. Histamine poisoning in tuberculous patients on ingestion of tropical fish. J Trop Med Hyg (1978) 81, 243–5.
Uragoda CG. Histamine intoxication with isoniazid and a species of fish. Ceylon Med J (1978) 23, 109–10.
Miki M, Ishikawa T, Okayama H. An outbreak of histamine poisoning after ingestion of the ground saury paste in eight patients taking isoniazid in a tuberculous ward. Intern Med (2005) 44, 1133–6.
Diao Y et al. Histamine like reaction in tuberculosis patients taking fishes containing much of histamine under treatment with isoniazid in 277 cases. Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi (1986) 9, 267–9, 317–18.
O’Sullivan TL. Drug-food interaction with isoniazid resembling anaphylaxis. Ann Pharmacother (1997) 31, 928–9.
Nguyen M, Beringer P, Wong-Beringer A, Louie S, Gill M, Gurevitch A. Effect of continuous enteral feedings (TF) on oral bioavailability (F) of linezolid (LZD) in hospitalized patients. Abstracts of the 43 rd Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, Chicago, Il, 2003, 43, 36.
Welshman IR, Sisson TA, Jungbluth GL, Stalker D, Hopkins NK. Linezolid absolute bioavailability and the effect of food on oral bioavailability. Biopharm Drug Dispos (2001) 22, 91–7.
Islinger F, Dehghanyar P, Sauermann R, Burger C, Kloft C, Muller M, Joukhader C. The effect of food on plasma and tissue concentrations of linezolid after multiple doses. Int J Antimicrob Agents (2006) 27, 108–12.
Antal EJ, Hendershot PE, Batts DH, Sheu W-P, Hopkins NK, Donaldson KM. Linezolid, a novel oxazolidinone antibiotic: assessment of monoamine oxidase inhibition using pressor response to oral tyramine. J Clin Pharmacol (2001) 41, 552–62.
Cantarini MV, Painter CJ, Gilmore EM, Bolger C, Watkins CL, Hughes AM. Effect of oral linezolid on the pressor response to intravenous tyramine. Br J Clin Pharmacol (2004) 58, 470–5.
Roller S, Lode H, Stelzer I, Deppermann KM, Boeckh M, Koeppe P. Pharmacokinetics of loracarbef and interaction with acetylcysteine. Eur J Clin Microbiol Infect Dis (1992) 11, 851–5.
DeSante KA, Zeckel ML. Pharmacokinetic profile of loracarbef. Am J Med (1992) 92 (Suppl 6A), 16S–19S.
Lutz M, Espinoza J, Arancibia A, Araya M, Pacheco I, Brunser O. Effect of structured dietary fiber on bioavailability of amoxicillin. Clin Pharmacol Ther (1987) 42, 220–4.
Koo WWK, Ke J, Tam YK, Finegan BA, Marriage B. Pharmacokinetics of ampicillin during parenteral nutrition. J Parenter Enteral Nutr (1990) 14, 279–82.
Welling PG, Huang H, Koch PA, Craig WA, Madsen PO. Bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects. J Pharm Sci (1977) 66, 549–52.
Eshelman FN, Spyker DA. Pharmacokinetics of amoxicillin and ampicillin: crossover study of the effect of food. Antimicrob Agents Chemother (1978) 14, 539–43.
Staniforth DH, Lillystone RJ, Jackson D. Effect of food on the bioavailability and tolerance of clavulanic acid/amoxycillin combination. J Antimicrob Chemother (1982) 10, 131–9.
Neuvonen PJ, Elonen E, Pentikainen PJ. Comparative effect of food on absorption of ampicillin and pivampicillin. J Int Med Res (1977) 5, 71–6.
Sommers DK, van Wyk M, Moncrieff J, Schoeman HS. Influence of food and reduced gastric acidity on the bioavailability of bacampicillin and cefuroxime axetil. Br J Clin Pharmacol (1984) 18, 535–9.
Magni L, Sjöberg B, Sjövall J, Wessman J. Clinical pharmacological studies with bacampicillin. Chemotherapy (1976) 5, 109–114.
Ali HM. The effect of Sudanese food and chloroquine on the bioavailability of ampicillin from bacampicillin tablets. Int J Pharmaceutics (1981) 9, 185–90.
Bergdahl S, Eriksson M, Finkel Y, Lännergren K. Oral absorption of flucloxacillin in infants and young children. Acta Pharmacol Toxicol (Copenh) (1986) 58, 255–8.
Babalola CP, Iwheye GB, Olaniyi AA. Effect of proguanil interaction on bioavailability of cloxacillin. J Clin Pharm Ther (2002) 27, 461–4.
Fernandez CA, Menezes JP, Ximenes J. The effect of food on the absorption of pivampicillin and a comparison with the absorption of ampicillin potassium. J Int Med Res (1973) 1, 530–3.
McCracken GH, Ginsburg CM, Clahsen JC, Thomas ML. Pharmacologic evaluation of orally administered antibiotics in infants and children: effect of feeding on bioavailability. Pediatrics (1978) 62, 738–43.
Staniforth DH, Clarke HL, Horton R, Jackson D, Lau D. Augmentin bioavailability following cimetidine, aluminium hydroxide and milk. Int J Clin Pharmacol Ther Toxicol (1985) 23, 154–7.
Hasegawa T, Yamaki K, Nadai M, Muraoka I, Wang L, Takagi K, Nabeshima T. Lack of effect of Chinese medicines on bioavailability of ofloxacin in healthy volunteers. Int J Clin Pharmacol Ther (1994) 32, 57–61.
Hasegawa T, Yamaki K-I, Muraoka I, Nadai M, Takagi K, Nabeshima T. Effects of traditional Chinese medicines on pharmacokinetics of levofloxacin. Antimicrob Agents Chemother (1995) 39, 2135–7.
Neuvonen PJ, Kivistö KT, Lehto P. Interference of dairy products with the absorption of ciprofloxacin. Clin Pharmacol Ther (1991) 50, 498–502.
Hoogkamer JFW, Kleinbloesem CH. The effect of milk consumption on the pharmacokinetics of fleroxacin and ciprofloxacin in healthy volunteers. Drugs (1995) 49 (Suppl 2), 346–8.
Lehto P, Kivistö KT. Effects of milk and food on the absorption of enoxacin. Br J Clin Pharmacol (1995) 39, 194–6.
Bertino JS, Nafziger AN, Wong M, Stragand L, Puleo C. Effects of a fat- and calcium-rich breakfast on pharmacokinetics of fleroxacin administered in single and multiple doses. Antimicrob Agents Chemother (1994) 38, 499–503.
Shiba K, Kusajima H, Momo K. The effects of aluminium hydroxide, cimetidine, ferrous sulfate, green tea and milk on pharmacokinetics of gatifloxacin in healthy humans. J Antimicrob Chemother (1999) 44 (Suppl A), 141.
Lehto PL, Kivistö KT. Different effects of products containing metal ions on the absorption of lomefloxacin. Clin Pharmacol Ther (1994) 56, 477–82.
Stass H, Kubitza D. Effects of dairy products on the oral bioavailability of moxifloxacin, a novel 8-methoxyfluoroquinolone, in healthy volunteers. Clin Pharmacokinet (2001) 40 (Suppl 1) 33–8.
Kivistö KT, Ojala-Karlsson P, Neuvonen PJ. Inhibition of norfloxacin absorption by dairy products. Antimicrob Agents Chemother (1992) 36, 489–91.
Dudley MN, Marchbanks CR, Flor SC, Beals B. The effect of food or milk on the absorption kinetics of ofloxacin. Eur J Clin Pharmacol (1991) 41, 569–71.
Neuvonen PJ, Kivistö KT. Milk and yoghurt do not impair the absorption of ofloxacin. Br J Clin Pharmacol (1992) 33, 346–8.
Mueller BA, Brierton DG, Abel SR, Bowman L. Effect of enteral feeding with Ensure on oral bioavailabilities of ofloxacin and ciprofloxacin. Antimicrob Agents Chemother (1994) 38, 2101–5.
Noer BL, Angaran DM. The effect of enteral feedings on ciprofloxacin pharmacokinetics. Pharmacotherapy (1990) 10, 254.
Piccolo ML, Toossi Z, Goldman M. Effect of coadministration of a nutritional supplement on ciprofloxacin absorption. Am J Hosp Pharm (1994) 51, 2697–9.
Sowinski KM, Abel SR, Clark WR, Mueller BA. Effect of gender on relative oral bioavailability of ciprofloxacin and ofloxacin when administered with an enteral feeding product. Pharmacotherapy (1997) 17, 1112.
Healy DP, Brodbeck MC, Clendening CE. Ciprofloxacin absorption is impaired in patients given enteral feedings orally and via gastrostomy and jejunostomy tubes. Antimicrob Agents Chemother (1996) 40, 6–10.
Yuk JH, Nightingale CH, Quintiliani R, Yeston NS, Orlando R, Dobkin ED, Kambe JC, Sweeney KR, Buonpane EA. Absorption of ciprofloxacin administered through a nasogastric tube or a nasoduodenal tube in volunteers and patients receiving enteral nutrition. Diagn Microbiol Infect Dis (1990) 13, 99–102.
Yuk JH, Nightingale CH, Sweeney KR, Quintiliani R, Lettieri JT, Frost RW. Relative bioavailability in healthy volunteers of ciprofloxacin administered through a nasogastric tube with and without enteral feeding. Antimicrob Agents Chemother (1989) 33, 1118–20.
de Marie S, VandenBergh MFQ, Buijk SLCE, Bruining H, van Vliet A, Kluytmans JAJW, Mouton JW. Bioavailability of ciprofloxacin after multiple enteral and intravenous doses in ICU patients with severe gram-negative intra-abdominal infections. Intensive Care Med (1998) 24, 343–6.
Mimoz O, Binter V, Jacolot A, Edouard A, Tod M, Petitjean O, Samii K. Pharmacokinetics and absolute bioavailability of ciprofloxacin administered through a nasogastric tube with continuous enteral feeding to critically ill patients. Intensive Care Med (1998) 24, 1047–51.
Wright DH, Pietz SL, Konstantinides FN, Rotschafer JC. Decreased in vitro fluoroquinolone concentrations after admixture with an enteral feeding formulation. J Parenter Enteral Nutr (2000) 24, 42–8.
Burkhardt O, Stass H, Thuss U, Borner K, Welte T. Effects of enteral feeding on the oral bioavailability of moxifloxacin in healthy volunteers. Clin Pharmacokinet (2005) 44, 969–76.
Höffken G, Lode H, Wiley R, Glatzel TD, Sievers D, Olschewski T, Borner K, Koeppe T. Pharmacokinetics and bioavailability of ciprofloxacin and ofloxacin: effect of food and antacid intake. Rev Infect Dis (1988) 10 (Suppl 1), S138–S139.
Frost RW, Carlson JD, Dietz AJ, Heyd A, Lettieri JT. Ciprofloxacin pharmacokinetics after a standard or high-fat/high-calcium breakfast. J Clin Pharmacol (1989) 29, 953–5.
Verho M, Malerczyk V, Dagrosa E, Korn A. The effect of food on the pharmacokinetics of ofloxacin. Curr Med Res Opin (1986) 10, 166–71.
Dudley MN, Marchbanks CR, Flor SC, Beals B. The effect of food or milk on the absorption kinetics of ofloxacin. Eur J Clin Pharmacol (1991) 41, 569–71.
Hooper WD, Dickinson RG, Eadie MJ. Effect of food on absorption of lomefloxacin. Antimicrob Agents Chemother (1990) 34, 1797–9.
Somogyi AA, Bochner F, Keal JA, Rolan PE, Smith M. Effect of food on enoxacin absorption. Antimicrob Agents Chemother (1987) 31, 638–9.
Allen A, Bygate E, Clark D, Lewis A, Pay V. The effect of food on the bioavailability of oral gemifloxacin in healthy volunteers. Int J Antimicrob Agents (2000) 16, 45–50.
Johnson RD, Dorr MB, Hunt TL, Jensen BK, Talbot GH. Effects of food on the pharmacokinetics of sparfloxacin. Clin Ther (1999) 21, 982–91.
Neuhofel AL, Wilton JH, Victory JM, Hejmanowski LG, Amsden GW. Lack of bioequivalence of ciprofloxacin when administered with calcium-fortified orange juice: a new twist on an old interaction. J Clin Pharmacol (2002) 42, 461–6.
Wallace AW, Victory JM, Amsden GW. Lack of bioequivalence of gatifloxacin when coadministered with calcium-fortified orange juice in healthy volunteers. J Clin Pharmacol (2003) 43, 92–6.
Wallace AW, Victory JM, Amsden GW. Lack of bioequivalence when levofloxacin and calcium-fortified orange juice are coadministered to healthy volunteers. J Clin Pharmacol (2003) 43, 539–44.
Amsden GW, Whitaker A-M. Johnson PW. Lack of bioequivalence of levofloxacin when coadministered with a mineral-fortified breakfast of juice and cereal. J Clin Pharmacol (2003) 43, 990–95.
Cohn SM, Sawyer MD, Burns GA, Tolomeo C, Milner KA. Enteric absorption of ciprofloxacin during tube feeding in the critically ill. J Antimicrob Chemother (1996) 38, 871–6.
Scheiner J, Altemeier WA. Experimental study of factors inhibiting absorption and effective therapeutic levels of declomycin. Surg Gynecol Obstet (1962) 114, 9–14.
Rosenblatt JE, Barrett JE, Brodie JL, Kirby WMM. Comparison of in vitro activity and clinical pharmacology of doxycycline with other tetracyclines. Antimicrob Agents Chemother (1966) 6, 134–41.
Meyer FP, Specht H, Quednow B, Walther H. Influence of milk on bioavailability of doxycycline — new aspects. Infection (1989) 17, 245–6.
Mattila MJ, Neuvonen PJ, Gothoni G, Hackman CR. Interference of iron preparations and milk with the absorption of tetracyclines. Int Congr Ser (1972) 254, 128–33.
Saux M-C, Mosser J, Pontagnier H, Leng B. Pharmacokinetic study of doxycycline polyphosphate after simultaneous ingestion of milk. Eur J Drug Metab Pharmacokinet (1983) 8, 43–9.
Leyden JJ. Absorption of minocycline hydrochloride and tetracycline hydrochloride. Effect of food, milk, and iron. J Am Acad Dermatol (1985) 12, 308–12.
Jung H, Rivera O, Reguero MT, Rodríguez JM, Moreno-Esparza R. Influence of liquids (coffee and orange juice) on the bioavailability of tetracycline. Biopharm Drug Dispos (1990) 11, 729–34.
Cook HJ, Mundo CR, Fonseca L, Gasque L, Moreno-Esparza R. Influence of the diet on bioavailability of tetracycline. Biopharm Drug Dispos (1993) 14, 549–53.
Albert A, Rees CW. Avidity of the tetracyclines for the cations of metals. Nature (1956) 177, 433–4.
Siewert M, Blume H, Stenzhorn G, Kieferndorf U, Lenhard G. Zur Qualitätsbeurteilung von doxycyclinhaltigen ertigarzneimitteln.3. Mitteilung: Vergleichende Bioverfügbarkeitsstudie unter Berücksichtigung einer Einnahme mit Milch. Pharm Ztg (1990) 3, 96–102.
Suvarna R, Pirmohamed M, Henderson L. Possible interaction between warfarin and cranberry juice. BMJ (2003) 327, 1454.
Grant P. Warfarin and cranberry juice: an interaction? J Heart Valve Dis (2004) 13, 25–6.
Rindone JP, Murphy TW. Warfarin-cranberry juice interaction resulting in profound hypoprothrombinemia and bleeding. Am J Ther (2006) 13, 283–4.
Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther (2006) 79, 125–33.
Isele H. Tödliche Blutung unter Warfarin plus Preiselbeersaft. Liegt’s an der Salizylsäure? MMW Fortschr Med (2004) 146, 13.
Melander A, Wåhlin E. Enhancement of dicoumarol bioavailability by concomitant food intake. Eur J Clin Pharmacol (1978) 14, 441–4.
Simon LS, Likes KE. Hypoprothrombinemic response due to ice cream. Drug Intell Clin Pharm (1978) 12, 121–2.
Blackshaw CA, Watson VA. Interaction between warfarin and ice cream. Pharm J (1990) 244, 318.
O’Reilly RA, Rytand DA. ‘Resistance’ to warfarin due to unrecognized vitamin K supplementation. N Engl J Med (1980) 303, 160–1.
Westfall LK. An unrecognized cause of warfarin resistance. Drug Intell Clin Pharm (1981) 15, 131.
Lader EW, Yang L, Clarke A. Warfarin dosage and vitamin K in Osmolite. Ann Intern Med (1980) 93, 373–4.
Lee M, Schwartz RN, Sharifi R. Warfarin resistance and vitamin K. Ann Intern Med (1981) 94, 140–1.
Michaelson R, Kempin SJ, Navia B, Gold JWM. Inhibition of the hypoprothrombinemic effect of warfarin (Coumadin ® ) by Ensure-Plus, a dietary supplement. Clin Bull (1980) 10, 171–2.
Zallman JA, Lee DP, Jeffrey PL. Liquid nutrition as a cause of warfarin resistance. Am J Hosp Pharm (1981) 38, 1174.
Griffith LD, Olvey SE, Triplett WC, Stotter Cuddy ML. Increasing prothrombin times in a warfarin-treated patient upon withdrawal of Ensure Plus. Crit Care Med (1982) 10, 799–800.
Parr MD, Record KE, Griffith GL, Zeok JV, Todd EP. Effect of enteral nutrition on warfarin therapy. Clin Pharm (1982) 1, 274–6.
Kutsop JJ. Update on vitamin K 1 content of enteral products. Am J Hosp Pharm (1984) 41, 1762.
Howard PA, Hannaman KN. Warfarin resistance linked to enteral nutrition products. J Am Diet Assoc (1985) 85, 713–15.
Martin JE, Lutomski DM. Warfarin resistance and enteral feedings. J Parenter Enteral Nutr (1989) 13, 206–8.
Petretich DA. Reversal of Osmolite-warfarin interaction by changing warfarin administration time. Clin Pharm (1990) 9, 93.
Watson AJM, Pegg M, Green JRB. Enteral feeds may antagonise warfarin. BMJ (1984) 288, 557.
Oren B, Shvartzman P. Unsuspected source of vitamin K in patients treated with anticoagulants: a case report. Fam Pract (1989) 6, 151–2.
Van Iersel MB, Blenke AAM, Kremer HPH, Hekster YA. Een patiënt met verminderde gevoeligheid voor acenocoumarol tijdens gebruik van sondevoeding. Ned Tijdschr Geneeskd (2004) 148, 1155–6.
Streif W, Marzinotto AV, Massicotte P, Chan AKC, Julian JA, Mitchell L. Analysis of warfarin therapy in pediatric patients: a prospective cohort study of 319 patients. Blood (1999) 94, 3007–14.
Lutomski DM, Palascak JE, Bower RH. Warfarin resistance associated with intravenous lipid administration. J Parenter Enteral Nutr (1987) 11, 316–18.
MacLaren R, Wachsman BA, Swift DK, Kuhl DA. Warfarin resistance associated with intravenous lipid administration: discussion of propofol and review of the literature. Pharmacotherapy (1997) 17, 1331–7.
Helphingstine CJ, Bistrian BR. New Food and Drug Administration requirements for inclusion of vitamin K in adult parenteral multivitamins. J Parenter Enteral Nutr (2003) 27, 220–4.
Penrod LE, Allen JB, Cabacungan LR. Warfarin resistance and enteral feedings: 2 case reports and a supporting in vitro study. Arch Phys Med Rehabil (2001) 82, 1270–3.
Monterrey-Rodríguez J, Feliú JF, Rivera-Miranda GC. Interaction between warfarin and mango fruit. Ann Pharmacother (2002) 36, 940–1.
Schurgers LJ, Shearer MJ, Hamulyák K, Stöcklin E, Vermeer C. Effect of vitamin K intake onthe stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood (2004) 104, 2682–9.
Kudo T. Warfarin antagonism of natto and increase in serum vitamin K by intake of natto. Artery (1990) 17, 189–201.
Cambria-Kiely JA. Effect of soy milk on warfarin efficacy. Ann Pharmacother (2002) 36, 1893–6.
Gaddi A, Sangiorgi Z, Ciarrocchi A, Braiato A, Descovich GC. Hypocholesterolemic soy protein diet and resistance to warfarin therapy. Curr Ther Res (1989) 45, 1006–10.
Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis (2000) 30, 298–307.
Blickstein D, Shaklai M, Inbal A. Warfarin antagonism by avocado. Lancet (1991) 337, 914–15.
Taylor JR, Wilt VM. Probable antagonism of warfarin by green tea. Ann Pharmacother (1999) 33, 426–8.
Booth SL, Madabushi HT, Davidson KW, Sadowski JA. Tea and coffee brews are not dietary sources of vitamin K-1 (phylloquinone). J Am Diet Assoc (1995) 95, 82–3.
Greenblatt DJ, von Moltke LL, Perloff ES, Luo Y, Harmatz JS, Zinny MA. Interaction of flurbiprofen with cranberry juice, grape juice, tea, and fluconazole: in vitro and clinical studies. Clin Pharmacol Ther (2006) 79, 125–33.
Pedersen FM, Hamberg O, Hess K, Ovesen L. The effect of dietary vitamin K on warfarin-induced anticoagulation. J Intern Med (1991) 229, 517–20.
Udall JA, Krock LB. A modified method of anticoagulant therapy. Curr Ther Res (1968) 10, 207–11.
Udall JA. Human sources and absorption of vitamin K in relation to anticoagulation stability. JAMA (1965) 194, 127–9.
Ovesen L, Lyduch S, Idorn ML. The effect of a diet rich in brussel sprouts on warfarin pharmacokinetics. Eur J Clin Pharmacol (1988) 33, 521–3.
Anon. Leafy vegetables in diet alter prothrombin time in patients taking anticoagulant drugs. JAMA (1964) 187, 27.
Qureshi GD, Reinders P, Swint JJ, Slate MB. Acquired warfarin resistance and weight-reducing diet. Arch Intern Med (1981) 141, 507–9.
Kempin SJ. Warfarin resistance caused by broccoli. N Engl J Med (1983) 308, 1229–30.
Chow WH, Chow TC, Tse TM, Tai YT, Lee WT. Anticoagulation instability with life-threatening complication after dietary modification. Postgrad Med J (1990) 66, 855–7.
Walker FB. Myocardial infarction after diet-induced warfarin resistance. Arch Intern Med (1984) 144, 2089–90.
Karlson B, Leijd B, Hellström A. On the influence of vitamin K-rich vegetables and wine on the effectiveness of warfarin treatment. Acta Med Scand (1986) 220, 347–50.
Schurgers LJ, Shearer MJ, HamulyáK K, Stöcklin E, Vermeer C. Effect of vitamin K intake on the stability of oral anticoagulant treatment: dose-response relationships in healthy subjects. Blood (2004) 104, 2682–9.
Kalra PA, Cooklin M, Wood G, O’Shea GM, Holmes AM. Dietary modification as a cause of anticoagulation instability. Lancet (1988) ii, 803.
Shearer MJ, Bach A, Kohlmeier M. Chemistry, nutritional sources, tissue distribution and metabolism of vitamin K with special reference to bone health. J Nutr (1996) 126, 1181S–1186S.
Schurgers LJ, Vermeer C. Determination of phylloquinone and menaquinones in food. Effect of food matrix on circulating vitamin K concentrations. Haemostasis (2000) 30, 298–307.
Bartle WR, Madorin P, Ferland G. Seaweed, vitamin K, and warfarin. Am J Health-Syst Pharm (2001) 58, 2300.
Flannery EP, MacDonald BS, O’Leary DS, McGinty JM. Japanese-restaurant syndrome. N Engl J Med (1971) 285, 414.
Lubetsky A, Dekel-Stern E, Chetrit A, Lubin F, Halkin H. Vitamin K intake and sensitivity to warfarin in patients consuming regular diets. Thromb Haemost (1999) 81, 396–9.
Couris R, Tataronis G, McCloskey W, Oertel L, Dallal G, Dwyer J, Blumberg JB. Dietary vitamin K variability affects International normalized ratio (INR) coagulation indices. Int J Vitam Nutr Res (2006) 76, 65–74.
Khan T, Wynne H, Wood P, Torrance A, Hankey C, Avery P, Kesteven P, Kamali F. Dietary vitamin K influences intra-individual variability in anticoagulant response to warfarin. Br J Haematol (2004) 124, 348–54.
Franco V, Polanczyk CA, Clausell N, Rohde LE. Role of dietary vitamin K intake in chronic oral anticoagulation: prospective evidence from observational and randomized protocols. Am J Med (2004) 116, 651–6.
Sconce E, Khan T, Mason J, Noble F, Wynne H, Kamali F. Patients with unstable control have a poorer dietary intake of vitamin K compared to patients with stable control of anticoagulation. Thromb Haemost (2005) 93, 872–5.
Sorano GG, Biondi G, Conti M, Mameli G, Licheri D, Marongiu F. Controlled vitamin K content diet for improving the management of poorly controlled anticoagulated patients: a clinical practice proposal. Haemostasis (1993) 23, 77–82.
Gijsbers BLMG, Jie K-SG, Vermeer C. Effect of food composition on vitamin K absorption in human volunteers. Br J Nutr (1996) 76, 223–9.
Booth SL, Suttie JW. Dietary intake and adequacy of vitamin K. J Nutr (1998) 128, 785–8.
Booth SL, Centurelli MA. Vitamin K: a practical guide to the dietary management of patients on warfarin. Nutr Rev (1999) 57, 288–96.
Couris RR, Tataronis GR, Booth SL, Dallal GE, Blumberg JB, Dwyer JT. Development of a self-assessment instrument to determine daily intake and variability of dietary vitamin K. J Am Coll Nutr (2000) 19, 801–6.
van Rooij J, van der Meer FJM, Schoemaker HC, Cohen AF. Comparison of the effect of grapefruit juice and cimetidine on pharmacokinetics and anticoagulant effect of a single dose of acenocoumarol. Br J Clin Pharmacol (1993) 35, 548P.
Sullivan DM, Ford MA, Boyden TW. Grapefruit juice and the response to warfarin. Am J Health-Syst Pharm (1998) 55, 1581–3.
Dresser GK, Munoz C, Cruikshank M, Kovacs M, Spence JD. Grapefruit juice-warfarin interaction in anticoagulated patients. Clin Pharmacol Ther (1999) 65, 193.
Bartle WR. Grapefruit juice might still be factor in warfarin response. Am J Health-Syst Pharm (1999) 56, 676.
Yue, Q-Y, Jansson K. Herbal drug Curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. J Am Geriatr Soc (2001) 49, 838.
Yu CM, Chan JCN, Sanderson JE. Chinese herbs and warfarin potentiation by ‘Danshen’. J Intern Med (1997) 241, 337–9.
Izzat MB, Yim APC, El-Zufari MH. A taste of Chinese medicine. Ann Thorac Surg (1998) 66, 941–2.
Lo ACT, Chan K, Yeung JHK, Woo KS. The effects of Danshen (Salvia miltiorrhiza) on pharmacokinetics and dynamics of warfarin in rats. Eur J Drug Metab Pharmacokinet (1992) 17, 257–62.
Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy (1999) 19, 870–6.
Ellis GR, Stephens MR. Untitled report. BMJ (1999) 319, 650.
Sunter W. Warfarin and garlic. Pharm J (1991) 246, 722.
Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H, Niihara Y. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr (2006) 136 (3 Suppl), 793S–795S.
Shalansky S, Neall E, Lo M, Abd-Elmessih E, Vickars L, Lynd L. The impact of complementary and alternative medicine use on warfarin-related adverse outcomes. Pharmacotherapy (2002) 22, 1345.
German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. Br J Urol (1995) 76, 518.
Rose KD, Croissant PD, Parliament CF, Levin MP. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery (1990) 26, 880–2.
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 59, 425–32.
Krüth P, Brosi E, Fux R, Mörike K, Gleiter CH. Ginger-associated overanticoagulation by phenprocoumon. Ann Pharmacother (2004) 38, 257–60.
Lesho EP, Saullo L, Udvari-Nagy S. A 76-year-old woman with erratic anticoagulation. Cleve Clin J Med (2004) 71, 651–6 .
Argento A, Tiraferri E, Marzaloni M. Anticoagulanti orali e piante medicinali. Una interazione emergente. Ann Ital Med Int (2000) 15, 139–43.
Braun L. Herb-drug interaction guide. Aust Fam Physician (2001) 30, 473–6.
Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother (2000) 34, 1478–82.
Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q 10 and ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost (2002) 87, 1075–6.
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 59, 425–32.
Lai C-F, Chang C-C, Fu C-H, Chen C-M. Evaluation of the interaction between warfarin and ginkgo biloba extract. Pharmacotherapy (2002) 22, 1326.
Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology (1998) 50, 1933.
Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother (2000) 34, 1478–82.
Mohutsky MA, Anderson GA, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther (2006) 13, 24–31.
Yuan C-S, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. Brief communication: American ginseng reduces warfarin’s effect in healthy patients. Ann Intern Med (2004) 141, 23–27. Importance and management.
Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health-Syst Pharm (1997) 54, 692–3.
Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology (2003) 99, 111.
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 57, 592–99.
Chiffoleau A, Huguenin H, Veyrac G, Argaiz V, Dupe D, Kayser M, Bourin M, Jolliet P. Interaction entre mélilot et acénocoumarol ? (mélilot-ruscus aculeatus). Therapie (2001) 56, 321–7.
Hogan RP. Hemorrhagic diathesis caused by drinking an herbal tea. JAMA (1983) 249, 2679–80.
Plotnikoff GA, McKenna D, Watanabe K, Blumenthal M. Ann Intern Med (2004) 141, 893–4.
Zhu M, Chan KW, Ng LS, Chang Q, Chang S, Li RC. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol (1999) 51, 175–80.
Hopkins MP, Androff L, Benninghoff AS. Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol (1988) 159, 1121–2.
Greenspan EM. Ginseng and vaginal bleeding. JAMA (1983) 249, 2018.
Kuo S-C, Teng C-M, Leed J-C, Ko F-N, Chen S-C, Wu T-S. Antiplatelet components in Panax ginseng. Planta Med (1990) 56, 164–7.
Lam AY, Elmer GW, Mohutsky M. Possible interaction between warfarin and Lycium barbarum. Ann Pharmacother (2001) 35, 1199–1201.
Wong ALN, Chan TYK. Interaction between warfarin and the herbal product quilinggao. Ann Pharmacother (2003) 37, 836–8.
Maurer A, Johne A, Bauer S, Brockmöller J, Donath F, Roots I, Langheinrich M, Hübner W-D. Interaction of St John’s wort extract with phenprocoumon. Eur J Clin Pharmacol (1999) 55, A22.
Bon S, Hartmann, Kuhn M. Johanniskraut: Ein Enzyminduktor? Schweiz Apothekerzeitung (1999) 16, 535–6.
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 57, 592–9.
Yue Q-Y, Bergquist C, Gerdén B. Safety of St John’s wort (Hypericum perforatum). Lancet (2000) 355, 576–7.
Bransgrove LL. Interaction between warfarin and a vitamin K-containing nutritional supplement: a case report. J Herb Pharmacother (2001) 1, 85–89.
Carr ME, Klotz J, Bergeron M. Coumadin resistance and the vitamin supplement “Noni”. Am J Hematol (2004) 77, 103–4.
Iven H, Lerche L, Kaschube M. Influence of quinine and quinidine on the pharmacokinetics of phenprocoumon in rat and man. Eur J Pharmacol (1990) 183, 662.
Clark DJ. Clinical curio: warfarin and tonic water. BMJ (1983) 286, 1258.
Pirk LA, Engelberg R. Hypoprothrombinemic action of quinine sulfate. JAMA (1945) 128, 1093–5.
Pirk LA, Engelberg R. Hypoprothrombinemic action of quinine sulfate. Am J Med Sci (1947) 213, 593–7.
Page RC, de Beer EJ, Orr ML. Prothrombin studies using Russell viper venom. II. Relation of clotting time to prothrombin concentration in human plasma. J Lab Clin Med (1941) 27, 197–201.
Quick AJ. Effect of synthetic vitamin K and quinine sulfate on the prothrombin level. J Lab Clin Med (1946) 31, 79–84.
Aslam M, Stockley IH. Interaction between curry ingredient (karela) and drug (chlorpropamide). Lancet (1979) i, 607.
Leatherdale BA, Panesar KR, Singh G, Atkins TW, Bailey CJ, Bignell AHC. Improvement in glucose tolerance due to Momordica charantia (karela). BMJ (1981) 282, 1823–4.
Tongia A, Tongia SK, Dave M. Phytochemical determination and extraction of Momordica charantia fruit and its hypoglycemic potentiation of oral hypoglycemic drugs in diabetes mellitus (NIDDM). Indian J Physiol Pharmacol (2004) 48, 241–44.
Welihinda J, Karunanayake EH, Sheriff MHR, Jaysinghe KSA . Effect of Momordica charantia on the glucose tolerance in maturity onset diabetes. J Ethnopharmacol (1986) 17, 277–82.
Akhtar MS. Trial of Momordica Charantia Linn (Karela) powder in patients with maturity-onset diabetes. J Pakistan Med Assoc (1982) 32, 106–7.
Srivastava Y, Venkatakrishna-Bhatt H, Verma Y, Venkaiah K, Raval BH. Antidiabetic and adaptogenic properties of Momordica charantia extract: an experimental and clinical evaluation. Phytother Res (1993) 7, 285–9.
Hulin A, Wavelet M, Desbordes JM. Intoxication aiguë par Momordica charantia (sorrossi). A propos de deux cas. Sem Hop Paris (1988) 64, 2847–8.
Hruska MW, Cheong JA, Langaee TY, Frye RF. Effect of St John’s wort administration on CYP2C8 mediated rosiglitazone metabolism. Clin Pharmacol Ther (2005) 77, P35.
Wang Z, Gorski JC, Hamman MA, Huang S-M, Lesko LJ, Hall SD. The effects of St John’s wort (Hypericum perforatum) on human cytochrome P450 activity. Clin Pharmacol Ther (2001) 70, 317–26.
Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin H-H, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide, and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med (2005) 71, 331–7.
Senzaki A, Okubo Y, Matuura M, Kojima T, Toru M. Clinical studies on effects of Saiko-ka-ryukotsu-borei-to (TJ-12) for adult patients with symptomatic localization-related epilepsy. Rinsho Seishin Igaku (1993) 22, 641–6.
Ohnishi N, Nakasako S, Okada K, Umehara S, Takara K, Nagasawa K, Yoshioka M, Kuroda K, Yokoyama T. Studies on interactions between traditional herbal and Western medicines. IV: Lack of pharmacokinetic interactions between Saiko-ka-ryukotsu-borei-to and carbamazepine in rats. Eur J Drug Metab Pharmacokinet (2001) 26, 129–35.
Chen LC, Chou MH, Lin MF, Yang LL. Lack of pharmacokinetic interaction between valproic acid and a traditional Chinese medicine, Paeoniae Radix, in healthy volunteers. J Clin Pharm Ther (2000) 25, 453–9.
Ohnishi N, Yonekawa Y, Nakasako S, Nagasawa K, Yokoyama T, Yoshioka M, Kuroda K. Studies on interactions between traditional herbal and Western medicines. I. Effects of Sho-seiryu-to on the pharmacokinetics of carbamazepine in rats. Biol Pharm Bull (1999) 22, 527–31.
Lau KK, Lai CK, Chan AYM. Phenytoin poisoning after using Chinese proprietary medicines. Hum Exp Toxicol (2000) 19, 385–6.
Bonin B, Vandel P, Vandel S, Kantelip JP. Effect of grapefruit intake on carbamazepine bioavailability: a case report. Therapie (2001) 56, 69–71.
Garg SK, Kumar N, Bhargava VK, Prabhakar SK. Effect of grapefruit juice on carbamazepine bioavailability in patients with epilepsy. Clin Pharmacol Ther (1998) 64, 286–8.
Ameer B, Weintraub RA. Drug interactions with grapefruit juice. Clin Pharmacokinet (1997) 33, 103–21.
Hidaka M, Okumura M, Fujita K-I, Ogikubo T, Yamasaki K, Iwakiri T, Setoguchi N, Arimori K. Effects of pomegranate juice on human cytochrome P450 3A (CYP3A) and carbamazepine pharmacokinetics in rats. Drug Metab Dispos (2005) 33, 644–8.
Gidal BE, Maly MM, Budde J, Lensmeyer GL, Pitterle ME, Jones JC. Effect of a high-protein meal on gabapentin pharmacokinetics. Epilepsy Res (1996) 23, 71–6.
Gidal BE, Maly MM, Kowalski JW, Rutecki PA, Pitterle ME, Cook DE. Gabapentin absorption: effect of mixing with foods of varying macronutrient composition. Ann Pharmacother (1998) 32, 405–9.
Parnell J, Sheth R, Limdi N, Gidal BE. Oral absorption of gabapentin syrup is not impaired by concomitant administration with various beverages or enteral nutrition supplement. Epilepsia (2001) 42 (Suppl 7), 91.
Johansson Ö, Wahlin-Boll E, Lindberg T, Melander A. Opposite effects of carbohydrate and protein on phenytoin absorption in man. Drug Nutr Interact (1983) 2, 139–44.
Sekikawa H, Nakano M, Takada M, Arita T. Influence of dietary components on the bioavailability of phenytoin. Chem Pharm Bull (Tokyo) (1980) 28, 2443–9.
Kennedy MC, Wade DN. The effect of food on the absorption of phenytoin. Aust N Z J Med (1982) 12, 258–61.
Longe RL, Smith OB. Phenytoin interaction with an oral feeding results in loss of seizure control. J Am Geriatr Soc (1988) 36, 542–4.
Taylor DM, Massey CA, Willson WG, Dhillon S. Lowered serum phenytoin concentrations during therapy with liquid food concentrates. Ann Pharmacother (1993) 27, 369.
Marvel ME, Bertino JS. Comparative effects of an elemental and a complex enteral feeding formulation on the absorption of phenytoin suspension. J Parenter Enteral Nutr (1991) 15, 316–8.
Nishimura LY, Armstrong EP, Plezia PM, Iacono RP. Influence of enteral feedings on phenytoin sodium absorption from capsules. Drug Intell Clin Pharm (1988) 22, 130–3.
Guidry JR, Eastwood TF, Curry SC. Phenytoin absorption in volunteers receiving selected enteral feedings. West J Med (1989) 150, 659–61.
Summers VM, Grant R. Nasogastric feeding and phenytoin interaction. Pharm J (1989) 243, 181.
Bauer LA. Interference of oral phenytoin absorption by continuous nasogastric feedings. Neurology (1982) 32, 570–2.
Ozuna J, Friel P. Effect of enteral tube feeding on serum phenytoin levels. J Neurosurg Nurs (1984) 16, 289–91.
Pearce GA. Apparent inhibition of phenytoin absorption by an enteral nutrient formula. Aust J Hosp Pharm (1988) 18, 289–92.
Worden JP, Wood CA, Workman CH. Phenytoin and nasogastric feedings. Neurology (1984) 34, 132.
Hatton RC. Dietary interaction with phenytoin. Clin Pharm (1984) 3, 110–11.
Weinryb J, Cogen R. Interaction of nasogastric phenytoin and enteral feeding solution. J Am Geriatr Soc (1989) 37, 195–6.
Maynard GA, Jones KM, Guidry JR. Phenytoin absorption from tube feedings. Arch Intern Med (1987) 147, 1821.
Doak KK, Haas CE, Dunnigan KJ, Reiss RA, Reiser JR, Huntress J, Altavela JL. Bioavailability of phenytoin acid and phenytoin sodium with enteral feedings. Pharmacotherapy (1998) 18, 637–45.
Rodman DP, Stevenson TL, Ray TR. Phenytoin malabsorption after jejunostomy tube delivery. Pharmacotherapy (1995) 15, 801–5.
Miller SW, Strom JG. Stability of phenytoin in three enteral nutrient formulas. Am J Hosp Pharm (1988) 45, 2529–32.
Hooks MA, Longe RL, Taylor AT, Francisco GE. Recovery of phenytoin from an enteral nutrient formula. Am J Hosp Pharm (1986) 43, 685–8.
Krueger KA, Garnett WR, Comstock TJ, Fitzsimmons WE, Karnes HT, Pellock JM. Effect of two administration schedules of an enteral nutrient formula on phenytoin bioavailability. Epilepsia (1987) 28, 706–12.
Fleisher D, Sheth N, Kou JH. Phenytoin interaction with enteral feedings administered through nasogastric tubes. J Parenter Enteral Nutr (1990) 14, 513–16.
Gilbert S. How to minimize interaction between phenytoin and enteral feedings: two approaches. A Strategic approach. Nutr Clin Pract (1996) 11, 28–30.
Faraji B, Yu P-P. Serum phenytoin levels of patients on gastrostomy tube feeding. J Neurosci Nurs (1998) 30, 55–9.
Hatton J, Magnuson B. How to minimize interaction between phenytoin and enteral feedings: two approaches. B Therapeutic options. Nutr Clin Pract (1996) 11, 30–1.
Issy AM, Lanchote VL, de Carvalho D, Silva HC. Lack of kinetic interaction between valproic acid and citrus pectin. Ther Drug Monit (1997) 19, 516–20.
Banfield C, Gupta S, Marino M, Lim J, Affrime M. Grapefruit juice reduces the oral bioavailability of fexofenadine but not desloratadine. Clin Pharmacokinet (2002) 41, 311–18.
Dresser GK, Bailey DG, Leake BF, Schwarz UI, Dawson PA, Freeman DJ, Kim RB. Fruit juices inhibit organic anion transporting polypeptide–mediated drug uptake to decrease the oral availability of fexofenadine. Clin Pharmacol Ther (2002) 71, 11–20.
Dresser GK, Kim RB, Bailey DG. Effect of grapefruit juice volume on the reduction of fexofenadine bioavailability: possible role of organic anion transporting polypeptides. Clin Pharmacol Ther (2005) 77, 170–7.
Dresser GK, Kim RB, Bailey DG. Duration of grapefruit juice effect on fexofenadine interaction. Clin Pharmacol Ther (2003) 73, P48.
Benton RE, Honig PK, Zamani K, Cantilena LR, Woosley RL. Grapefruit juice alters terfenadine pharmacokinetics, resulting in prolongation of repolarization on the electrocardiogram. Clin Pharmacol Ther (1996) 59, 383–8.
Honig PK, Wortham DC, Lazarev A, Cantilena LR. Grapefruit juice alters the systemic bioavailability and cardiac repolarization of terfenadine in poor metabolizers of terfenadine. J Clin Pharmacol (1996) 36, 345–51.
Clifford CP, Adams DA, Murray S, Taylor GW, Wilkins MR, Boobis AR, Davies DS. The cardiac effects of terfenadine after inhibition of its metabolism by grapefruit juice. Eur J Clin Pharmacol (1997) 52, 311–15.
Rau SE, Bend JR, Arnold JMO, Tran LT, Spence JD, Bailey DG. Grapefruit juice–terfenadine single-dose interaction: magnitude, mechanism, and relevance. Clin Pharmacol Ther (1997) 61, 401–9.
Anon. Grapefruit juice and terfenadine: the “final straw”. Pharm J (1997) 258, 618.
Wang Z, Hamman MA, Huang S-M, Lesko LJ, Hall SD. Effect of St John’s wort on the pharmacokinetics of fexofenadine. Clin Pharmacol Ther (2002) 71, 414–20.
Dresser GK, Schwarz UI, Wilkinson GR, Kim RB. Coordinate induction of both cytochrome P4503A and MDR1 by St John’s wort in healthy subjects. Clin Pharmacol Ther (2003) 73, 41–50.
Mathew NT, Tietjen GE, Lucker C. Serotonin syndrome complicating migraine pharmacotherapy. Cephalalgia (1996) 16, 323–7.
Bobik A, Jennings G, Skews H, Esler M, McLean A. Low oral bioavailability of dihydroergotamine and first-pass extraction in patients with orthostatic hypotension. Clin Pharmacol Ther (1981) 30, 673–9.
Schneider W, Krumpl G, Mayer N, Raberger G. The effects of nitroglycerin on exercise-induced regional myocardial contractile dysfunction are not diminished by pretreatment with dihydroergotamine. Br J Pharmacol (1987) 92, 87–95.
Gatterer R. Ergotism as complication of thromboembolic prophylaxis with heparin and dihydroergotamine. Lancet (1986) II, 638–639.
Warmuth-Metz M. Ergotismus der unteren Extremität als Folge einer DHE-Heparin-Thrombose prophylaxe. Radiologe (1988) 28, 491–3.
Jahn R. Ergotismus – ein Risiko bei der Thromboseprophylaxe? Zentralbl Chir (1985) 110, 482–5.
Rem JA, Gratzl O, Follath F, Pult I. Ergotism as complication of thromboembolic prophylaxis with heparin-dihydroergotamine. Lancet (1987) I, 219.
Schran HF, Bitz DW, DiSerio FJ, Hirsh J. The pharmacokinetics and bioavailability of subcutaneously administered dihydroergotamine, heparin and the dihydroergotamine-heparin combination. Thromb Res. (1983) 31, 51–67.
Horowitz RS, Dart RC, Gomez HF. Clinical ergotism with lingual ischemia induced by a clarithromycin-ergotamine interaction. Arch Intern Med (1996) 156, 456–8.
Ausband SC, Goodman PE. An unusual case of clarithromycin associated ergotism. J Emerg Med (2001) 21, 411–13.
Francis H, Tyndall A, Webb J. Severe vascular spasm due to erythromycin-ergotamine interaction. Clin Rheumatol (1984) 3, 243–6.
Lagier G, Castot A, Riboulet G, Boesh C. Un cas d’ergotisme mineur semblant en rapport avec une potentialisation de l’ergotamine par l’éthylsuccinate d’érythromycine. Therapie (1979) 34, 515–21.
Neveux E, Lesgourgues B, Luton J-P, Guilhaume B, Bertagna, Picard J. Ergotisme aigu par association proprionate d’érythromycine-dihydroergotamine. Nouv Presse Med (1981) 10, 2830.
Collet AM, Moncharmont D, San Marco JL, Eissinger F, Pinot JJ, Laselve L. Ergotisme iatrogène: rôle de l’association tartrate d’ergotamine-propionate d’érythromycine. Sem Hop Paris (1982) 58, 1624–6.
Boucharlat J, Franco A, Carpentier P, Charignon Y, Denis B, Hommel M. Ergotisme en milieu psychiatrique par association D.H.E. propionate d’erythromycine. A propos d’une observation. Ann Med Psychol (Paris) (1980) 138, 292–6
Leroy F, Asseman P, Pruvost P, Adnet P, Lacroix D, Thery C. Dihydroergotamine-erythromycin-induced ergotism. Ann Intern Med (1988) 109, 249.
Ghali R, De Léan J, Douville Y, Noël H-P, Labbé R. Erythromycin-associated ergotamine intoxication: arteriographic and electrophysiologic analysis of a rare cause of severe ischemia of the lower extremities and associated ischemic neuropathy. Ann Vasc Surg (1993) 7, 291–6.
Bird PA, Sturgess AD. Clinical ergotism with severe bilateral upper limb ischaemia precipitated by an erythromycin-ergotamine interaction. Aust N Z J Med (2000) 30, 635–6.
Karam B, Farah E, Ashoush R, Jebara V, Ghayad E. Ergotism precipitated by erythromycin: a rare case of vasospasm. Eur J Vasc Endovasc Surg (2000) 19, 96–8.
Grolleau JY, Martin M, de la Guerrande B, Barrier J, Peltier P. Ergotism aigu lors d’une association josamycine/tartrate d’ergotamine. Therapie (1981) 36, 319–21.
Couet W, Mathieu HP, Fourtillan JB. Effect of ponsinomycin on the pharmacokinetics of dihydroergotamine administered orally. Fundam Clin Pharmacol (1991) 5, 47–52.
Monsarrat M, Lefebvre D, Parraguette J, Vaysse C, Bastide G. Ergotisme aigu par association ergotamine-oleandomycine. Nouv Presse Med (1982) 11, 603.
Franco A, Bourlard P, Massot C, Lecoeur J, Guidicelli H, Bessard G. Ergotisme aigu par association dihydroergotamine-triacétyloléandomycine. Nouv Presse Med (1978) 7, 205.
Lesca H, Ossard D, Reynier P. Les risques de l’association tri-acétyl-oléandomycine et tartrate d’ergotamine. Nouv Presse Med (1976) 5, 1832–3.
Hayton AC. Precipitation of acute ergotism by triacetyloleandomycin. N Z Med J (1969) 69, 42.
Dupuy JC, Lardy P, Seaulau P, Kervoelen P, Paulet J. Spasmes artériels systémiques. Tartrate d’ergotamine. Arch Mal Coeur (1979) 72, 86–91.
Bigorie B, Aimez P, Soria RJ, Samama F di Maria G, Guy-Grand B, Bour H. L’association triacétyl oléandomycin-tartrate d’ergotamine est-elle dangereuse? Nouv Presse Med (1975) 4, 2723–5.
Vayssairat M, Fiessinger J-N, Becquemin M-H, Housset E. Association dihydroergotamine et triacétyloléandomycine. Rôle dans une nécrose digitale iatrogène. Nouv Presse Med (1978) 7, 2077.
Matthews NT, Havill JH. Ergotism with therapeutic doses of ergotamine tartrate. N Z Med J (1979) 89, 476–7.
Chignier E, Riou R, Descotes J, Meunier P, Courpron P, Vignon G. Ergotisme iatrogène aigu par association médicamenteuse diagnostiqué par exploration non invasive (vélocimétrie à effet Doppler). Nouv Presse Med (1978) 7, 2478.
Bacourt F, Couffinhal J-C. Ischémie des membres par association dihydroergotamine-tri-acétyloléandomycine. Nouvelle observation. Nouv Presse Med (1978) 7, 1561.
Baudouy PY, Mellat M, Velleteau de Moulliac M. Infarctus du myocarde provoqué par l’association tartrate d’ergotamine-troléandomycine. Rev Med Interne (1988) 9, 420–2.
Pessayre D, Larrey D, Funck-Brentano C, Benhamou JP. Drug interactions and hepatitis produced by some macrolide antibiotics. J Antimicrob Chemother (1985) 16 (Suppl A), 181–94.
Hopkins S. Clinical toleration and safety of azithromycin. Am J Med (1991) 91 (Suppl 3A), 40S–45S.
Lode H. The pharmacokinetics of azithromycin and their clinical significance. Eur J Clin Microbiol Infect Dis (1991) 10, 807–12.
Joyce DA, Gubbay SS. Arterial complications of migraine treatment with methysergide and parenteral ergotamine. BMJ (1982) 285, 260–1.
Galer BS, Lipton RB, Solomon S, Newman LC, Spierings ELH. Myocardial ischemia related to ergot alkaloids: a case report and literature review. Headache (1991) 31, 446–50.
Vaughan-Lane T. Gangrene induced by methysergide and ergotamine. J Bone Joint Surg Br. (1979) 61–B, 213–14.
Rosenthal E, Sala F, Chichmanian R-M, Batt M, Cassuto J-P. Ergotism related to concurrent administration of ergotamine tartrate and indinavir. JAMA (1999) 281, 987.
Mortier E, Pouchot J, Vinceneux P, Lalande M. Ergotism related to interaction between nelfinavir and ergotamine. Am J Med (2001) 110, 594.
Caballero-Granado FJ, Viciana P, Cordero E, Gómez-Vera MJ, del Nozal M, López-Cortés LF. Ergotism related to concurrent administration of ergotamine tartrate and ritonavir in an AIDS patient. Antimicrob Agents Chemother (1997), 41,1207.
Phan TG, Agaliotis D, White G, Britton WJ. Ischaemic peripheral neuritis secondary to ergotism associated with ritonavir therapy. Med J Aust (1999) 171, 502, 504.
Pardo Rey C, Yebra M, Borrallo M, Vega A, Ramos A, Montero MC. Irreversible coma, ergotamine and ritonavir. Clin Infect Dis (2003) 37, e72–3.
Tribble MA, Gregg CR, Margolis DM, Amirkhan R, Smith JW. Fatal ergotism induced by an HIV protease inhibitor. Headache (2002) 42, 694–5.
Montero A, Giovannoni AG, Tvrde PL. Leg ischemia in a patient receiving ritonavir and ergotamine. Ann Intern Med (1999) 130, 329–30.
Liaudet L, Buclin T, Jaccard C, Eckert P. Severe ergotism associated with interaction between ritonavir and ergotamine. BMJ (1999) 318, 771.
Blanche P, Rigolet A, Gombert B, Ginsburg C, Salmon D, Sicard D. Ergotism related to a single dose of ergotamine tartrate in an AIDS patient treated with ritonavir. Postgrad Med J (1999) 75, 546–7.
Vila A, Mykietiuk A, Bonvehì P, Temporiti E, Urueña A, Herrera F. Clinical ergotism induced by ritonavir. Scand J Infect Dis (2001) 33, 788–9.
Baldwin ZK, Ceraldi C. Ergotism associated with HIV antiviral protease inhibitor therapy. J Vasc Surg (2003) 37, 676–8.
Spiegel M, Schmidauer C, Kampfl A, Sarcletti M, Poewe W. Cerebral ergotism under treatment with ergotamine and ritonavir. Neurology (2001) 57, 743–4.
Amblard P, Reymond JL, Franco A, Beani JC, Carpentier P, Lemonnier D, Bessard G. Ergotisme. Forme mineure par association dihydroergotamine-chlorhydrate de doxycycline, étude capillaroscopique. Nouv Presse Med (1978) 7, 4148–9.
Dupuy JC, Lardy P, Seaulau P, Kervoelen P, Paulet J. Spasmes artériels systémiques. Tartrate d’ergotamine. Arch Mal Coeur (1979) 72, 86–91.
Van Gestel R, Noirhomme Ph. Ergotism aigu par association de tartrate d’ergotamine et de doxycycline. Louvain Med (1984) 103, 207–208.
L’Yvonnet M, Boillot A, Jacquet AM, Barale F, Grandmottet P, Zurlinden B, Gillet JY. A propos d’un cas exceptionnel d’intoxication aigue par un dérivé de l’ergot de seigle. Gynecologie (1974) 25, 541–3.
Sibertin-Blanc M. Les dangers de l’ergotisme a propos de deux observations. Arch Med Ouest (1977) 9, 265–6.
Gunnarsson P O, Davidsson T, Andersson S-B, Backman C, Johansson S-Å. Impairment of estramustine phosphate absorption by concurrent intake of milk and food. Eur J Clin Pharmacol (1990) 38, 189–93.
Boyle FM. Adverse interaction of herbal medicine with breast cancer treatment. Med J Aust (1997) 167, 286.
Eagon CL, Elm MS, Teepe AG, Eagon PK. Medicinal botanicals: estrogenicity in rat uterus and liver. Proc Am Assoc Cancer Res (1997) 38, 293.
Rosenblatt M, Mindel J. Spontaneous hyphema associated with ingestion of Ginkgo biloba extract. N Engl J Med (1997) 336, 1108.
Ly J, Percy L, Dhanani S. Use of dietary supplements and their interactions with prescription drugs in the elderly. Am J Health-Syst Pharm (2002) 59, 1759–62.
Makino T, Wakushima H, Okamoto T, Okukubo Y, Deguchi Y, Kano Y. Pharmacokinetic and pharmacological interactions between ticlopidine hydrochloride and Kangen-Karyu – Chinese traditional herbal medicine. Phytother Res (2003) 17, 1021–4.
Rowin J, Lewis SL. Spontaneous bilateral subdural hematomas associated with chronic Ginkgo biloba ingestion. Neurology (1996) 46, 1775–6.
Vale S. Subarachnoid haemorrhage associated with Ginkgo biloba. Lancet (1998) 352, 36.
Gilbert GJ. Ginkgo biloba. Neurology (1997) 48, 1137.
Benjamin J, Muir T, Briggs K, Pentland B. A case of cerebral haemorrhage – can Ginkgo biloba be implicated? Postgrad Med J (2001) 77, 112–13.
Fessenden JM, Wittenborn W, Clarke L. Gingko biloba: a case report of herbal medicine and bleeding postoperatively from a laparoscopic cholecystectomy. Am Surg (2001) 67, 33–5.
Bramer SL, Forbes WP. Relative bioavailability and effects of a high fat meal on single dose cilostazol pharmacokinetics. Clin Pharmacokinet (1999) 37 (Suppl 2), 13–23.
Smits P, Aengevaeren WRM, Corstens FHM, Thien T. Caffeine reduces dipyridamole-induced myocardial ischemia. J Nucl Med (1989) 30, 1723–6.
Smits P, Straatman C, Pijpers E, Thien T. Dose-dependent inhibition of the hemodynamic response to dipyridamole by caffeine. Clin Pharmacol Ther (1991) 50, 529–37.
Daley PJ, Mahn TH, Zielonka JS, Krubsack AJ, Akhtar R, Bamrah VS. Effect of maintenance oral theophylline on dipyridamole–thallium-201 myocardial imaging using SPECT and dipyridamole-induced hemodynamic changes. Am Heart J (1988) 115, 1185–92.
Takeishi Y, Tono-oka I, Kubota I, Ikeda K, Masakane I, Chiba J, Abe S, Tsuiki K, Tomoike H. Intravenous aminophylline affects myocardial washout of thallium-201 after dipyridamole infusion. Am J Noninvasive Cardiol (1992) 6, 116–21.
Ranhosky A, Kempthorne-Rawson J, and the Intravenous Dipyridamole Thallium Imaging Study Group. The safety of intravenous dipyridamole thallium myocardial perfusion imaging. Circulation (1990) 81, 1205–9.
Picano E et al. on behalf of the Echo-Persantine International Cooperative Study Group. Safety of intravenous high-dose dipyridamole echocardiography. Am J Cardiol (1992) 70, 252–8.
Mikkelsen EJ. Caffeine and schizophrenia. J Clin Psychiatry (1978) 39, 732–5.
Kulhanek F, Linde OK, Meisenberg G. Precipitation of antipsychotic drugs in interaction with coffee or tea. Lancet (1979) ii, 1130.
Hirsch SR. Precipitation of antipsychotic drugs in interaction with tea or coffee. Lancet (1979) ii, 1130–1.
Lasswell WL, Wilkins JM, Weber SS. In vitro interaction of selected drugs with coffee, tea, and gallotannic acid. Drug Nutr Interact (1984) 2, 235–41.
Lasswell WL, Weber SS, Wilkins JM. In vitro interaction of neuroleptics and tricyclic antidepressants with coffee, tea, and gallotannic acid. J Pharm Sci (1984) 73, 1056–8.
Curry ML, Curry SH, Marroum PJ. Interaction of phenothiazine and related drugs and caffeinated beverages. DICP Ann Pharmacother (1991) 25, 437–8.
Cheeseman HJ, Neal MJ. Interaction of chlorpromazine with tea and coffee. Br J Clin Pharmacol (1981) 12, 165–9.
Bowen S, Taylor KM, Gibb IAM. Effect of coffee and tea on blood levels and efficacy of antipsychotic drugs. Lancet (1981) i, 1217–18.
Wallace SM, Suveges LG, Blackburn JL, Korchinski ED, Midha KK. Oral fluphenazine and tea and coffee drinking. Lancet (1981) ii, 691.
Gorski JC, Huang S-M, Pinto A, Hamman MA, Hilligoss JK, Zaheer NA, Desai M, Miller M, Hall SD. The effect of echinacea (Echinacea purpurea root) on cytochrome P450 activity in vivo. Clin Pharmacol Ther (2004) 75, 89–100.
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther (2004) 76, 428–40.
Bareggi SR, Pirola R, Truci G, Leva S, Smirna S. Effect of after-dinner administration on the pharmacokinetics of oral flunitrazepam and loprazolam. J Clin Pharmacol (1988) 28, 371–5.
Yasui-Furukori N, Takahata T, Kondo T, Mihara K, Kaneko S, Tateishi T. Time effects of food intake on the pharmacokinetics and pharmacodynamics of quazepam. Br J Clin Pharmacol (2003) 55, 382–8.
Kim Y, Morikawa M, Ohsawa H, Kou M, Ishida E, Igarashi J, Kajimoto T, Danno T, Nakata M, Yokoyama T, Tokuyama A, Nakamura Y, Kishimoto T. Effects of food on the pharmacokinetics and clinical efficacy of quazepam. Jpn J Neuropsychopharmacol (2003) 23, 205–10.
Yasui-Furukori N, Kondo T, Takahata T, Mihara K, Ono S, Kaneko S, Tateishi T. Effect of dietary fat content in meals on pharmacokinetics of quazepam. J Clin Pharmacol (2002) 42, 1335–40.
Markowitz JS, Donovan JL, DeVane CL, Sipkes L, Chavin KD. Multiple-dose administration of Ginkgo biloba did not affect cytochrome P-450 2D6 or 3A4 activity in normal volunteers. J Clin Psychopharmacol (2003) 23, 576–81.
Özdemir M, Aktan Y, Boydağ BS, Cingi MI, Musmul A. Interaction between grapefruit juice and diazepam in humans. Eur J Drug Metab Pharmacokinet (1998) 23, 55–9.
Sugimoto K-I, Araki N, Ohmori M, Harada K-I, Cui Y, Tsuruoka S, Kawaguchi A, Fujimura A. Interaction between grapefruit juice and hypnotic drugs: comparison of triazolam and quazepam. Eur J Clin Pharmacol (2006) 62, 209–15.
Kupferschmidt HHT, Ha HR, Ziegler WH, Meier PJ, Krähenbühl S. Interaction between grapefruit juice and midazolam in humans. Clin Pharmacol Ther (1995) 58, 20–8.
Vanakoski J, Mattila MJ, Seppälä T. Grapefruit juice does not enhance the effects of midazolam and triazolam in man. Eur J Clin Pharmacol (1996) 50, 501–8.
Hukkinen SK, Varhe A, Olkkola KT, Neuvonen PJ. Plasma concentrations of triazolam are increased by concomitant ingestion of grapefruit juice. Clin Pharmacol Ther (1995) 58, 127–31.
Lilja JJ, Kivistö KT, Backman JT, Neuvonen PJ. Effect of grapefruit juice dose on grapefruit juice–triazolam interaction: repeated consumption prolongs triazolam half-life. Eur J Clin Pharmacol (2000) 56, 411–15.
Tuncok Y, Akpinar O, Guven H, Akkoclu A. The effects of theophylline on serum alprazolam levels. Int J Clin Pharmacol Ther (1994) 32, 642–5.
Stirt JA. Aminophylline is a diazepam antagonist. Anesth Analg (1981) 60, 767–8.
Niemand D, Martinell S, Arvidsson S, Svedmyr N, Ekström-Jodal B. Aminophylline inhibition of diazepam sedation: is adenosine blockade of GABA-receptors the mechanism? Lancet (1984) i, 463–4.
Arvidsson SB, Ekström-Jodal B, Martinell SAG, Niemand D. Aminophylline antagonises diazepam sedation. Lancet (1982) 2, 1467.
Kleindienst G, Usinger P. Diazepam sedation is not antagonised completely by aminophylline. Lancet (1984) 1, 113.
Mattila MJ, Nuotto E. Caffeine and theophylline counteract diazepam effects in man. Med Biol (1983) 61, 337–43.
Mattila MJ, Palva E, Savolainen K. Caffeine antagonizes diazepam effects in man. Med Biol (1982) 60, 121–3.
Henauer SA, Hollister LE, Gillespie HK, Moore F. Theophylline antagonizes diazepam-in-duced psychomotor impairment. Eur J Clin Pharmacol (1983) 25, 743–7.
Meyer BH, Weis OF, Müller FO. Antagonism of diazepam by aminophylline in healthy volunteers. Anesth Analg (1984) 63, 900–2.
Gürel A, Elevli M, Hamulu A. Aminophylline reversal of flunitrazepam sedation. Anesth Analg (1987) 66, 333–6.
Wangler MA, Kilpatrick DS. Aminophylline is an antagonist of lorazepam. Anesth Analg (1985) 64, 834–6.
Kanto J, Aaltonen L, Himberg J-J, Hovi-Viander M. Midazolam as an intravenous induction agent in the elderly: a clinical and pharmacokinetic study. Anesth Analg (1986) 65, 15–20.
Gallen JS. Aminophylline reversal of midazolam sedation. Anesth Analg (1989) 69, 268.
Sleigh JW. Failure of aminophylline to antagonize midazolam sedation. Anesth Analg (1986) 65, 540.
Gaillard J-M, Sovilla J-Y, Blois R. The effects of clonazepam, caffeine and the combination of the two drugs on human sleep. In: Koella WP, Rüther E, Schulz H, eds. Sleep ‘84. New York: Gustav Fischer Verlag; 1985: pp. 314–15.
Mattila ME, Mattila MJ, Nuotto E. Caffeine moderately antagonizes the effects of triazolam and zopiclone on the psychomotor performance of healthy subjects. Pharmacol Toxicol (1992) 70, 286–9.
Salvà P, Costa J. Clinical pharmacokinetics and pharmacodynamics of zolpidem: therapeutic implications. Clin Pharmacokinet (1995) 29, 142–53.
Ghoneim MM, Hinrichs JV, Chiang C-K, Loke WH. Pharmacokinetic and pharmacodynamic interactions between caffeine and diazepam. J Clin Psychopharmacol (1986) 6, 75–80.
Lilja JJ, Kivistö KT, Backman JT, Lamberg TS, Neuvonen PJ. Grapefruit juice substantially increases plasma concentrations of buspirone. Clin Pharmacol Ther (1998) 64, 655–60.
Dannawi M. Possible serotonin syndrome after combination of buspirone and St John’s wort. J Psychopharmacol (2002) 16, 401.
Spinella M, Eaton LA. Hypomania induced by herbal and pharmaceutical psychotropic medicines following mild traumatic brain injury. Brain Inj (2002) 16, 359–67.
Raaska K, Raitasuo V, Laitila J, Neuvonen PJ. Effect of caffeine-containing versus decaffeinated coffee on serum clozapine concentrations in hospitalised patients. Basic Clin Pharmacol Toxicol (2004) 94, 13–18.
Hägg S, Spigset O, Mjörndal T, Dahlqvist R. Effect of caffeine on clozapine pharmacokinetics in healthy volunteers. Br J Clin Pharmacol (2000) 49, 59–63.
Carrillo JA, Herraiz AG, Ramos SI, Benitez J. Effects of caffeine withdrawal from the diet on the metabolism of clozapine in schizophrenic patients. J Clin Psychopharmacol (1998) 18, 311–16.
Beale MD, Pritchett JT, Kellner CH. Supraventricular tachycardia in a patient receiving ECT, clozapine, and caffeine. Convuls Ther (1994) 10, 228–31.
Vainer JL, Chouinard G. Interaction between caffeine and clozapine. J Clin Psychopharmacol (1994) 14, 284–5.
Odom-White A, de Leon J. Clozapine levels and caffeine. J Clin Psychiatry (1996) 57, 175–6.
Carrillo JA, Jerling M, Bertilsson L. Comments to “Interaction between caffeine and clozapine”. J Clin Psychopharmacol (1995) 15, 376–7.
Lane H-Y, Chiu C-C, Kazmi Y, Desai H, Lam YWF, Jan MW, Chang W-H. Lack of CYP3A4 inhibition by grapefruit juice and ketoconazole upon clozapine administration in vivo. Drug Metabol Drug Interact (2001) 18, 263–78.
Lane H-Y, Jann MW, Chang Y-C, Chiu C-C, Huang M-C, Lee S-H, Chang W-H. Repeated ingestion of grapefruit juice does not alter clozapine’s steady-state plasma levels, effectiveness, and tolerability. J Clin Psychiatry (2001) 62, 812–17.
Yasui N, Kondo T, Suzuki A, Otani K, Mihara K, Furukori H, Kaneko S, Inoue Y. Lack of significant pharmacokinetic interaction between haloperidol and grapefruit juice. Int Clin Psychopharmacol (1999) 14, 113–8.
de Maat MMR, Hoetelmans RMW, Mathôt RAA, van Gorp ECM, Meenhorst PL, Mulder JW, Beijnen JH. Drug interaction between St John’s wort and nevirapine. AIDS (2001) 15, 420–1.
Carver PL, Fleisher D, Zhou SY, Kaul D, Kazanjian P, Li C. Meal composition effects on the oral bioavailability of indinavir in HIV-infected patients. Pharm Res (1999) 16, 718–24.
Stone JA, Ju WD, Steritt A, Woolf EJ, Yeh KC, Deutsch P, Waldman S, Bjornsson TD. Effect of food on the pharmacokinetics of indinavir in man. Pharm Res (1996) 13 (Suppl 9), S414.
Quart BD, Chapman SK, Peterkin J, Webber S, Oliver S. Phase I safety, tolerance, pharmacokinetics and food effect studies of AG1343--a novel HIV protease inhibitor. The American Society for Microbiology in collaboration with NIH and CDC. 2 nd National Conference Human Retroviruses and Related Infections, Washington DC, 1995. Abstract LB3.
Bertz R, Shi H, Cavanaugh J, Hsu A. Effect of three vehicles, Advera ® , Ensure ® and chocolate milk, on the bioavailability of an oral liquid formulation of Norvir (Ritonavir). Intersci Conf Antimicrob Agents Chemother (1996) 36, 5.
Piscitelli SC, Burstein AH, Welden N, Gallicano KD, Falloon J. The effect of garlic supplements on the pharmacokinetics of saquinavir. Clin Infect Dis (2002) 34, 234–8.
Jacek H, Rentsch KM, Steinert HC, Pauli-Magnus C, Meier PJ, Fattinger K. No effect of garlic extract on saquinavir kinetics and hepatic CYP3A4 function measured by the erythromycin breath test. Clin Pharmacol Ther (2004) 75, P80.
Laroche M, Choudhri S, Gallicano K, Foster B. Severe gastrointestinal toxicity with concomitant ingestion of ritonavir and garlic. Can J Infect Dis (1998) 9 (Suppl A), 76A.
Gallicano K, Foster B, Choudhri S. Effect of short-term administration of garlic supplements on single-dose ritonavir pharmacokinetics in healthy volunteers. Br J Clin Pharmacol (2003) 55, 199–202.
McCrea J, Woolf E, Sterrett A, Matthews C, Deutsch P, Yeh KC, Waldman S, Bjornsson T. Effects of ketoconazole and other P-450 inhibitors on the pharmacokinetics of indinavir. Pharm Res (1996) 13 (Suppl 9), S485.
Penzak SR, Acosta EP, Turner M, Edwards DJ, Hon YY, Desai HD, Jann MW. Effect of Seville orange juice and grapefruit juice on indinavir pharmacokinetics. J Clin Pharmacol (2002) 42, 1165–70.
Wynn H, Shelton MJ, Bartos L, Difrancesco R, Hewitt RG. Grapefruit juice (GJ) increases gastric pH, but does not affect indinavir (IDV) exposure, in HIV patients. Intersci Conf Antimicrob Agents Chemother (1999) 39, 25.
Kupferschmidt HHT, Fattinger KE, Ha HR, Follath F, Krähenbühl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br J Clin Pharmacol (1998) 45, 355–9.
Eagling VA, Profit L, Back DJ. Inhibition of the CYP3A4-mediated metabolism and P-glycoprotein-mediated transport of the HIV-1 protease inhibitor saquinavir by grapefruit juice components. Br J Clin Pharmacol (1999) 48, 543–52.
Melander A, Danielson K, Scherstén B, Wåhlin E. Enhancement of the bioavailability of propranolol and metoprolol by food. Clin Pharmacol Ther (1977) 22, 108–12.
Liedholm H, Melander A. Concomitant food intake can increase the bioavailability of propranolol by transient inhibition of its presystemic primary conjugation. Clin Pharmacol Ther (1986) 40, 29–36.
McLean AJ, Isbister C, Bobik A, Dudley F. Reduction of first-pass hepatic clearance of propranolol by food. Clin Pharmacol Ther (1981) 30, 31–4.
Daneshmend TK, Roberts CJC. The influence of food on the oral and intravenous pharmacokinetics of a high clearance drug: a study with labetalol. Br J Clin Pharmacol (1982) 14, 73–8.
Dawes CP, Kendall MJ, Welling PG. Bioavailability of conventional and slow-release oxprenolol in fasted and nonfasted individuals. Br J Clin Pharmacol (1979) 7, 299–302.
John VA, Smith SE. Influence of food intake on plasma oxprenolol concentrations following oral administration of conventional and Oros preparations. Br J Clin Pharmacol (1985) 19, 191S–195S.
Kiger JL, Lavene D, Guillaume MF, Guerret M, Longchampt J. The effect of food and clopamide on the absorption of pindolol in man. Int J Clin Pharmacol Biopharm (1976) 13, 228–32.
Melander A, Stenberg P, Liedholm H, Scherstén B, Wåhlin-Boll E. Food-induced reduction in bioavailability of atenolol. Eur J Clin Pharmacol (1979) 16, 327–30.
Barnwell SG, Laudanski T, Dwyer M, Story MJ, Guard P, Cole S, Attwood D. Reduced bioavailability of atenolol in man: the role of bile acids. Int J Pharmaceutics (1993) 89, 245–50.
Lilja JJ, Raaska K, Neuvonen PJ. Effects of grapefruit juice on the pharmacokinetics of acebutolol. Br J Clin Pharmacol (2005) 60, 659–63.
Lilja JJ, Raaska K, Neuvonen PJ. Effects of orange juice on the pharmacokinetics of atenolol. Eur J Clin Pharmacol (2005) 61, 337–40.
Lilja JJ, Backman JT, Laitila J, Luurila H, Neuvonen PJ. Itraconazole increases but grapefruit juice greatly decreases plasma concentrations of celiprolol. Clin Pharmacol Ther (2003) 73, 192–8.
Lilja JJ, Juntti-Patinen L, Neuvonen PJ. Orange juice substantially reduces the bioavailability of the β -adrenergic-blocking agent celiprolol. Clin Pharmacol Ther (2004) 75, 184–90.
Schwarz UI, Seemann D, Oertel R, Miehlke S, Kuhlisch E, Fromm MF, Kim RB, Bailey DG, Kirch W. Grapefruit juice ingestion significantly reduces talinolol bioavailability. Clin Pharmacol Ther (2005) 77, 291–301.
Spahn-Langguth H, Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur J Pharm Sci (2001) 12, 361–7.
Smits P, Hoffmann H, Thien T, Houben H, van’t Laar A. Hemodynamic and humoral effects of coffee after β 1 -selective and nonselective β -blockade. Clin Pharmacol Ther (1983) 34, 153–8.
Freestone S, Ramsey LE. Effect of β -blockade on the pressor response to coffee plus smoking in patients with mild hypertension. Drugs (1983) 25 (Suppl 2), 141–5.
Bailey DG, Spence JD, Munoz C, Arnold JMO. Interaction of citrus juices with felodipine and nifedipine. Lancet (1991) 337, 268–9.
Edgar B, Bailey DG, Bergstrand R, Johnsson G, Lurje L. Formulation dependent interaction between felodipine and grapefruit juice. Clin Pharmacol Ther (1990) 47, 181.
Bailey DG, Spence JD, Edgar B, Bayliff CD, Arnold JMO. Ethanol enhances the hemodynamic effects of felodipine. Clin Invest Med (1989) 12, 357–62.
Edgar B, Bailey D, Bergstrand R, Johnsson G, Regårdh CG. Acute effects of drinking grapefruit juice on the pharmacokinetics and dynamics on felodipine – and its potential clinical relevance. Eur J Clin Pharmacol (1992) 42, 313–17.
Bailey DG, Arnold JMO, Munoz C, Spence JD. Grapefruit juice–felodipine interaction: mechanism, predictability, and effect of naringin. Clin Pharmacol Ther (1993) 53, 637–42.
Bailey DG, Bend JR, Arnold JMO, Tran LT, Spence JD. Erythromycin-felodipine interaction: magnitude, mechanism, and comparison with grapefruit juice. Clin Pharmacol Ther (1996) 60, 25–33.
Lundahl JUE, Regårdh CG, Edgar B, Johnsson G. The interaction effect of grapefruit juice is maximal after the first glass. Eur J Clin Pharmacol (1998) 54, 75–81.
Lundahl J, Regårdh CG, Edgar B, Johnsson G. Effects of grapefruit juice ingestion – pharmacokinetics and haemodynamics of intravenously and orally administered felodipine in healthy men. Eur J Clin Pharmacol (1997) 52, 139–45.
Malhotra S, Bailey DG, Paine MF, Watkins PB. Seville orange juice-felodipine interaction: comparison with dilute grapefruit juice and involvement of furocoumarins. Clin Pharmacol Ther (2001) 69, 14–23.
Dresser GK, Bailey DG, Carruthers SG. Grapefruit juice—felodipine interaction in the elderly. Clin Pharmacol Ther (2000) 68, 28–34.
Bailey DG, Arnold JMO, Bend JR, Tran LT, Spence JD. Grapefruit juice-felodipine interaction: reproducibility and characterization with the extended release drug formulation. Br J Clin Pharmacol (1995) 40, 135–40.
Lundahl J, Regårdh CG, Edgar B, Johnsson G. Relationship between time of intake of grapefruit juice and its effect on pharmacokinetics and pharmacodynamics of felodipine in healthy subjects. Eur J Clin Pharmacol (1995) 49, 61–7.
Uno T, Ohkubo T, Sugawara K, Higashiyama A, Motomura S, Ishizaki T. Effects of grapefruit juice on the stereoselective disposition of nicardipine in humans: evidence for dominant presystemic elimination at the gut site. Eur J Clin Pharmacol (2000) 56, 643–9.
Rashid J, McKinstry C, Renwick AG, Dirnhuber M, Waller DG, George CF. Quercetin, an in vitro inhibitor of CYP3A, does not contribute to the interaction between nifedipine and grapefruit juice. Br J Clin Pharmacol (1993) 36, 460–3.
Sigusch H, Hippius M, Henschel L, Kaufmann K, Hoffmann A. Influence of grapefruit juice on the pharmacokinetics of a slow release nifedipine formulation. Pharmazie (1994) 49, 522–4.
Rashid TJ, Martin U, Clarke H, Waller DG, Renwick AG, George CF. Factors affecting the absolute bioavailability of nifedipine. Br J Clin Pharmacol (1995) 40, 51–8.
Pisarïk P. Blood pressure-lowering effect of adding grapefruit juice to nifedipine and terazosin in a patient with severe renovascular hypertension. Arch Fam Med (1996) 5, 413–6.
Fuhr U, Maier A, Blume H, Mück W, Unger S, Staib AH. Grapefruit juice increases oral nimodipine bioavailability. Eur J Clin Pharmacol (1994) 47, A100.
Fuhr U, Maier-Brüggemann A, Blume H, Mück W, Unger S, Kuhlmann J, Huschka C, Zaigler M, Rietbrock S, Staib AH. Grapefruit juice increases oral nimodipine bioavailability. Int J Clin Pharmacol Ther (1998) 36, 126–32.
Soons PA, Vogels BAPM, Roosemalen MCM, Schoemaker HC, Uchida E, Edgar B, Lundahl J, Cohen AF, Breimer DD. Grapefruit juice and cimetidine inhibit stereoselective metabolism of nitrendipine in humans. Clin Pharmacol Ther (1991) 50, 394–403.
Bailey DG, Arnold JMO, Strong HA, Munoz C, Spence JD. Effect of grapefruit juice and naringin on nisoldipine pharmacokinetics. Clin Pharmacol Ther (1993) 54, 589–94.
Adigun AQ, Mudasiru Z. Clinical effects of grapefruit juice-nifedipine interaction in a 54-year-old Nigerian: a case report. J Natl Med Assoc (2002) 94, 276–8.
Takanaga H, Ohnishi A, Murakami H, Matsuo H, Higuchi S, Urae A, Irie S, Furuie H, Matsukuma K, Kimura M, Kawano K, Orii Y, Tanaka T, Sawada Y. Relationship between time after intake of grapefruit juice and the effect on pharmacokinetics and pharmacodynamics of nisoldipine in healthy subjects. Clin Pharmacol Ther (2000) 67, 201–14.
Josefsson M, Zackrisson A-L, Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur J Clin Pharmacol (1996) 51, 189–93.
Vincent J, Harris SI, Foulds G, Dogolo LC, Willavize S, Friedman HL. Lack of effect of grapefruit juice on the pharmacokinetics and pharmacodynamics of amlodipine. Br J Clin Pharmacol (2000) 50, 455–63.
Josefsson M, Ahlner J. Amlodipine and grapefruit juice. Br J Clin Pharmacol (2002) 53, 405.
Ohtani M, Kawabata S, Kariya S, Uchino K, Itou K, Kotaki H, Kasuyama K, Morikawa A, Seo I, Nishida N. Effect of grapefruit pulp on the pharmacokinetics of the dihydropyridine calcium antagonists nifedipine and nisoldipine. Yakugaku Zasshi (2002) 122, 323–9.
Bailey DG, Dresser GK, Kreeft JH, Munoz C, Freeman DJ, Bend JR. Grapefruit-felodipine interaction: effect of unprocessed fruit and probable active ingredients. Clin Pharmacol Ther (2000) 68, 468–77.
Sigusch H, Henschel L, Kraul H, Merkel U, Hoffman A. Lack of effect of grapefruit juice on diltiazem bioavailability in normal subjects. Pharmazie (1994) 49, 675–9.
Christensen H, Åsberg A, Holmboe A-B, Berg KJ. Coadministration of grapefruit juice increases systemic exposure of diltiazem in healthy volunteers. Eur J Clin Pharmacol (2002) 58, 515–20.
Zaidenstein R, Dishi V, Gips M, Soback S, Cohen N, Weissgarten J, Blatt A, Golik A. The effect of grapefruit juice on the pharmacokinetics of orally administered verapamil. Eur J Clin Pharmacol (1998) 54, 337–40.
Ho P-C, Ghose K, Saville D, Wanwimolruk S. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur J Clin Pharmacol (2000) 56, 693–8.
Fuhr U, Müller-Peltzer H, Kern R, Lopez-Rojas P, Jünemann M, Harder S, Staib AH. Effects of grapefruit juice and smoking on verapamil concentrations in steady state. Eur J Clin Pharmacol (2002) 58, 45–53.
Chayen R, Rosenthal T. Interaction of citrus juices with felodipine and nifedipine. Lancet (1991) 337, 854.
Bailey DG, Dresser GK, Bend JR. Bergamottin, lime juice, and red wine as inhibitors of cytochrome P450 3A4 activity: comparison with grapefruit juice. Clin Pharmacol Ther (2003) 73, 529–37.
Goosen TC, Cillié D, Bailey DG, Yu C, He K, Hollenberg PF, Woster PM, Cohen L, Williams JA, Rheeders M, Dijkstra HP. Bergamottin contribution to the grapefruit juice—felodipine interaction and disposition in humans. Clin Pharmacol Ther (2004) 76, 607–17.
Tannergren C, Engman H, Knutson L, Hedeland M, Bondesson U, Lennernäs H. St John’s wort decreases the bioavailability of R- and S-verapamil through induction of first-pass metabolism. Clin Pharmacol Ther (2004) 75, 298–309.
Melander A, Danielson K, Hanson A, Rudell B, Schersten B, Thulin T, Wåhlin E. Enhancement of hydralazine bioavailability by food. Clin Pharmacol Ther (1977) 22, 104–7.
Liedholm H, Wåhlin-Boll E, Hanson A, Melander A. Influence of food on the bioavailability of ‘real’ and ‘apparent’ hydralazine from conventional and slow-release preparations. Drug Nutr Interact (1982) 1, 293–302.
Walden RJ, Hernadez R, Witts D, Graham BR, Prichard BN. Effect of food on the absorption of hydralazine in man. Eur J Clin Pharmacol (1981) 20, 53–8.
Shepherd AM, Irvine NA, Ludden TM. Effect of food on blood hydralazine levels and response in hypertension. Clin Pharmacol Ther (1984) 36, 14–18.
Jackson SHD, Shepherd AMM, Ludden TM, Jamieson MJ, Woodworth J, Rogers D, Ludden LK, Muir KT. Effect of food on oral bioavailability of apresoline and controlled release hydralazine in hypertensive patients. J Cardiovasc Pharmacol (1990) 16, 624–8.
Semple HA, Koo W, Tam YK, Ngo LY, Coutts RT. Interactions between hydralazine and oral nutrients in humans. Ther Drug Monit (1991) 13, 304–8.
Wang D-J, Chu K-M, Chen J-D. Drug interaction between digoxin and bisacodyl. J Formos Med Assoc (1990) 89, 913, 915–9.
Woods MN, Ingelfinger JA. Lack of effect of bran on digoxin absorption. Clin Pharmacol Ther (1979) 26, 21–3.
Nordström M, Melander A, Robertsson E, Steen B. Influence of wheat bran and of a bulk-forming ispaghula cathartic on the bioavailability of digoxin in geriatric in-patients. Drug Nutr Interact (1987) 5, 67–9.
Johnson BF, Rodin SM, Hoch K, Shekar V. The effect of dietary fiber on the bioavailability of digoxin in capsules. J Clin Pharmacol (1987) 27, 487–90.
Brown DD, Juhl RP, Warner SL. Decreased bioavailability of digoxin due to hypocholesterolemic interventions. Circulation (1978) 58, 164–72.
Huupponen R, Seppälä P, Iisalo E. Effect of guar gum, a fibre preparation, on digoxin and penicillin absorption in man. Eur J Clin Pharmacol (1984) 26, 279–81.
Lembcke B, Häsler K, Kramer P, Caspary WF, Creuzfeldt W. Plasma digoxin concentrations during administration of dietary fibre (guar gum) in man. Z Gastroenterol (1982) 20, 164–7.
Walan A, Bergdahl B, Skoog M-L. Study of digoxin bioavailability during treatment with a bulk forming laxative (Metamucil). Scand J Gastroenterol (1977) 12 (Suppl 45), 111.
Ragueneau I, Poirier J-M, Radembino N, Sao AB, Funck-Brentano C, Jaillon P. Pharmacokinetic and pharmacodynamic drug interactions between digoxin and macrogol 4000, a laxative polymer, in healthy volunteers. Br J Clin Pharmacol (1999) 48, 453–6.
Floyd RA. Digoxin interaction with bran and high fiber foods. Am J Hosp Pharm (1978) 35, 660.
Hamamura J, Burros BC, Clemens RA, Smith CH. Dietary fiber and digoxin. Fedn Proc (1985) 44, 759.
Becquemont L, Verstuyft C, Kerb R, Brinkmann U, Lebot M, Jaillon P, Funck-Brentano C. Effect of grapefruit juice on digoxin pharmacokinetics in humans. Clin Pharmacol Ther (2001) 70, 311–6.
Parker RB, Yates CR, Soberman JE, Laizure SC. Effects of grapefruit juice on intestinal P-glycoprotein: evaluation using digoxin in humans. Pharmacotherapy (2003) 23, 979–87.
Xu J, Go ML, Lim L-Y. Modulation of digoxin transport across Caco-2 cell monolayers by citrus fruit juices: lime, lemon, grapefruit and pummelo. Pharm Res (2003) 20, 169–76.
Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song P-f, Hubbard MA, Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2006) 34, 69–74.
Scheinhost ME. Digoxin toxicity in a 26-year-old woman taking a herbal dietary supplement. J Am Osteopath Assoc (2001), 101, 444–6.
Longerich L, Johnson E, Gault MH. Digoxin-like factors in herbal teas. Clin Invest Med (1993) 16, 210–8.
Sweetman SC, ed. Martindale: The complete drug reference. 35 th ed. London: Pharmaceutical Press; 2007. p.2188.
Thürmann PA, Neff A, Fleisch J. Interference of uzara glycosides in assays of digitalis glycosides. Int J Clin Pharmacol Ther (2004) 42, 281–4.
Dasgupta A, Davis B, Wells A. Effect of plantain on therapeutic drug monitoring of digoxin and thirteen other common drugs. Ann Clin Biochem (2006) 43, 223–5.
Slifman NR, Obermeyer WR, Aloi BK, Musser SM, Correll WA, Cichowicz SM, Betz JM, Love LA. Contamination of botanical dietary supplements by Digitalis lanata. N Engl J Med (1998) 339, 806–11.
Mauro VF, Mauro LS, Kleshinski JF, Khuder SA, Wang Y, Erhardt PW. Impact of Ginkgo biloba on the pharmacokinetics of digoxin. Am J Ther (2003) 10, 247–51.
McRae S. Elevated serum digoxin levels in a patient taking digoxin and Siberian ginseng. Can Med Assoc J (1996) 155, 293–5.
Dasgupta A, Wu S, Actor J, Olsen M, Wells A, Datta P. Effect of Asian and Siberian ginseng on serum digoxin measurement by five digoxin immunoassays. Significant variation in digoxin-like immunoreactivity among commercial ginsengs. Am J Clin Pathol (2003) 119, 298–303.
Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2007) 35, 240–5.
Tankanow R, Tamer HR, Streetman DS, Smith SG, Welton JL, Annesley T, Aaronson KD, Bleske BE. Interaction study between digoxin and a preparation of hawthorn (Crataegus oxyacantha). J Clin Pharmacol (2003) 43, 637–42.
Gurley BJ, Swain A, Barone GW, Williams DK, Breen P, Yates CR, Stuart LB, Hubbard MA, Tong Y, Cheboyina S. Effect of goldenseal (Hydrastis canadensis) and kava kava (Piper methysticum) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2007) 35, 240–5.
Gurley BJ, Barone GW, Williams DK, Carrier J, Breen P, Yates CR, Song P-f, Hubbard MA, Tong Y, Cheboyina S. Effect of milk thistle (Silybum marianum) and black cohosh (Cimicifuga racemosa) supplementation on digoxin pharmacokinetics in humans. Drug Metab Dispos (2006) 34, 69–74.
And elić S. Bigeminija – rezultat interakcije digoksina i kantariona. Vojnosanit Pregl (2003) 60, 361–4.
Johne A, Brockmöller J, Bauer S, Maurer A, Langheinrich M, Roots I. Pharmacokinetic interaction of digoxin with an herbal extract from St John’s wort (Hypericum perforatum). Clin Pharmacol Ther (1999) 66, 338–45.
Mueller SC, Uehleke B, Woehling H, Petzsch M, Majcher-Peszynska J, Hehl E-M, Sievers H, Frank B, Riethling A-K, Drewelow B. Effect of St John’s wort dose and preparations on the pharmacokinetics of digoxin. Clin Pharmacol Ther (2004) 75, 546–57.
Arold G, Donath F, Maurer A, Diefenbach K, Bauer S, Henneicke-von Zepelin HH, Friede M, Roots I. No relevant interaction with alprazolam, caffeine, tolbutamide and digoxin by treatment with a low-hyperforin St John’s wort extract. Planta Med (2005) 71, 331–337.
Dürr D, Stieger B, Kullak-Ublick GA, Rentsch KM, Steinert HC, Meier PJ, Fattinger K. St John’s wort induces intestinal P-glycoprotein/MDR1 and intestinal and hepatic CYP3A4. Clin Pharmacol Ther (2000) 68, 598–604.
Committee on the Safety of Medicines (UK). Message from Professor A Breckenridge (Chairman of CSM) and Fact Sheet for Health Care Professionals, 29th February 2000.
Gibbs CJ, Lee HA. Milk-alkali syndrome due to Caved-S. J R Soc Med (1992) 85, 498–9.
Verburg FA, van Zanten RAA, Brouwer RML, Woittiez AJJ, Veneman TF. Een man met een ernstig klassiek melk-alkalisyndroom en een maagcarcinoom. Ned Tijdschr Geneeskd (2006) 150, 1624–7.
Gordon MV, Hamblin PS, McMahon LP. Life-threatening milk-alkali syndrome resulting from antacid ingestion during pregnancy. Med J Aust (2005) 182, 350–351.
Picolos MK, Lavis VR, Orlander PR. Milk–alkali syndrome is a major cause of hypercalcaemia among non-end-stage renal disease (non-ESRD) inpatients. Clin Endocrinol (Oxf) (2005) 63, 566–76.
McGuinness B, Logan JI. Milk alkali syndrome. Ulster Med J (2002) 71, 132–5.
Ennen CS, Magann EF. Milk-alkali syndrome presenting as acute renal insufficiency during pregnancy. Obstet Gynecol (2006) 108, 785–6.
George S, Clark JDA. Milk alkali syndrome – an unusual syndrome causing an unusual complication. Postgrad Med J (2000) 76, 422–4.
Uno T, Yasui-Furukori N, Takahata T, Sugawara K, Tateishi T. Lack of significant effect of grapefruit juice on the pharmacokinetics of lansoprazole and its metabolites in subjects with different CYP2C19 genotypes. J Clin Pharmacol (2005) 45, 690–4.
Tassaneeyakul W, Tassaneeyakul W, Vannaprasaht S, Yamazoe Y. Formation of omeprazole sulphone but not 5-hydroxyomeprazole is inhibited by grapefruit juice. Br J Clin Pharmacol (2000) 49, 139–44.
Yin OQP, Tomlinson B, Waye MMY, Chow AHL, Chow MSS. Pharmacogenetics and herb–drug interactions: experience with Gingko biloba and omeprazole. Pharmacogenetics (2004) 14, 841–50.
Wang LS, Zhou G, Zhu B, Wu J, Wang JG, Abd El-Aty AM, Li T, Liu J, Yang TL, Wang D, Zhong XY, Zhou HH. St John’s wort induces both cytochrome P450 3A4–catalyzed sulfoxidation and 2C19–dependent hydroxylation of omeprazole. Clin Pharmacol Ther (2004) 75, 191–7.
Schubert W, Cullberg G, Edgar B, Hedner T. Inhibition of 17 beta-estradiol metabolism by grapefruit juice in ovariectomized women. Maturitas (1994) 20, 155–63.
Weber A, Jäger R, Börner A, Klinger G, Vollanth R, Matthey K, Balogh A. Can grapefruit juice influence ethinylestradiol bioavailability? Contraception (1996) 53, 41–7.
Keogh A, Day R, Critchley L, Duggin G, Baron D. The effect of food and cholestyramine on the absorption of cyclosporine in cardiac transplant recipients. Transplant Proc (1988) 20, 27–30.
Santos P, Lourenço R, Camilo ME, Oliveira AG, Figueira I, Pereira ME, Ferreira B, Carmo JA, Lacerda JMF. Parenteral nutrition and cyclosporine: do lipids make a difference? A prospective randomized crossover trial. Clin Nutr (2001) 20, 31–6.
Johnston PE, Milstone A. Probable interaction of bergamottin and cyclosporine in a lung transplant recipient. Transplantation (2005) 79, 746.
Schwarz UI, Johnston PE, Bailey DG, Kim RB, Mayo G, Milstone A. Impact of citrus soft drinks relative to grapefruit juice on ciclosporin disposition. Br J Clin Pharmacol (2005) 62, 485–91.
Ducharme MP, Provenzano R, Dehoorne-Smith M, Edwards DJ. Trough concentrations of cyclosporine in blood following administration with grapefruit juice. Br J Clin Pharmacol (1993) 36, 457–9.
Yee GC, Stanley DL, Pessa LJ, Costa TD, Beltz SE, Ruiz J, Lowenthal DT. Effect of grapefruit juice on blood cyclosporine concentration. Lancet (1995) 345, 955–6.
Proppe DG, Hoch OD, McLean AJ, Visser KE. Influence of chronic ingestion of grapefruit juice on steady-state blood concentrations of cyclosporine A in renal transplant patients with stable graft function. Br J Clin Pharmacol (1995) 39, 337–8.
Min DI, Ku Y-M, Perry PJ, Ukah FO, Ashton K, Martin MF, Hunsicker LG. Effect of grapefruit juice on cyclosporine pharmacokinetics in renal transplant patients. Transplantation (1996) 62, 123–5.
Herlitz H, Edgar B, Hedner T, Lidman K, Karlberg I. Grapefruit juice: a possible source of variability in blood concentration of cyclosporin A. Nephrol Dial Transplant (1993) 8, 375.
Brunner L, Munar MY, Vallian J, Wolfson M, Stennett DJ, Meyer MM, Bennett WM. Interaction between cyclosporine and grapefruit juice requires long-term ingestion in stable renal transplant recipients. Pharmacotherapy (1998) 18, 23–9.
Emilia G, Longo G, Bertesi M, Gandini G, Ferrara L, Valenti C. Clinical interaction between grapefruit juice and cyclosporine: is there any interest for the hematologists? Blood (1998) 91, 362–3.
Edwards DJ, Fitzsimmons ME, Schuetz EG, Yasuda K, Ducharme MP, Warbasse LH, Woster PM, Schuetz JD, Watkins P. 6’,7’-dihydroxybergamottin in grapefruit juice and Seville orange juice: effects on cyclosporine disposition, enterocyte CYP3A4, and P-glycoprotein. Clin Pharmacol Ther (1999) 65, 237–44.
Ku Y-M, Min DI, Flanigan M. Effect of grapefruit juice on the pharmacokinetics of microemulsion cyclosporine and its metabolite in healthy volunteers: does the formulation difference matter? J Clin Pharmacol (1998) 38, 959–65.
Proppe D, Visser K, Hoch O, Bartels R, Meier H, McLean AJ. Differential influence on cyclosporin A metabolism by chronic grapefruit juice exposure. Eur J Clin Invest (1996) 26 (Suppl 1), A20.
Ioannides-Demos LL, Christophidis N, Ryan P, Angelis P, Liolios L, McLean AJ. Dosing implications of a clinical interaction between grapefruit juice and cyclosporine and metabolite concentrations in patients with autoimmune diseases. J Rheumatol (1997) 24, 49–54.
Hollander AAMJ, van Rooij J, Lentjes EGWM, Arbouw F, van Bree JB, Schoemaker RC, van Es LA, van der Woude FJ, Cohen AF. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther (1995) 57, 318–24.
Mehrsai AR, Pourmand G, Mansour D, Zand S, Rezaali A. Effect of grapefruit juice on serum concentration of cyclosporine in Iranian renal transplant patients. Transplant Proc (2003) 35, 2739–41.
Yee GC, Adams VR, Pessa L, Braddock RJ, Ruiz J, Lowenthal DT. Comparison of one versus two doses of grapefruit juice on oral cyclosporine pharmacokinetics. Pharmacotherapy (1997) 17, 1112.
Proppe D, Visser K, Bartels R, Hoch O, Meyer H, McLean AJ. Grapefruit juice selectively modifies cyclosporin A metabolite patterns in renal transplant patients. Clin Pharmacol Ther (1996) 59, 138.
Bistrup C, Nielsen FT, Jeppesen UE, Dieperink H. Effect of grapefruit juice on Sandimmun Neoral ® absorption among stable renal allograft recipients. Nephrol Dial Transplant (2001) 16, 373–7.
Lee M, Min DI, Ku Y-M, Flanigan M. Effect of grapefruit juice on pharmacokinetics of microemulsion cyclosporine in African American subjects compared with Caucasian subjects: does ethnic difference matter? J Clin Pharmacol (2001) 41, 317–23.
Brunner LJ, Pai K-S, Munar MY, Lande MB, Olyaei AJ, Mowry JA. Effect of grapefruit juice on cyclosporin A pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant (2000) 4, 313–21.
Ducharme MP, Warbasse LH, Edwards DJ. Disposition of intravenous and oral cyclosporine after administration with grapefruit juice. Clin Pharmacol Ther (1995) 57, 485–91.
Grenier J, Fradette C, Morelli G, Merritt GJ, Vranderick M, Ducharme MP. Pomelo juice, but not cranberry juice, affects the pharmacokinetics of cyclosporine in humans. Clin Pharmacol Ther (2006) 79, 255–62.
Johnston A, Holt DW. Effect of grapefruit juice on blood cyclosporin concentration. Lancet (1995) 346, 122–3.
Hollander AAMJ, van der Woude FJ, Cohen AF. Effect of grapefruit juice on blood cyclosporin concentration. Lancet (1995) 346, 123.
Yee GC, Lowenthal DT. Effect of grapefruit juice on blood cyclosporin concentration. Lancet (1995) 346, 123–4.
Light TD, Light JA. Acute renal transplant rejection possibly related to herbal medications. Am J Transplant (2003) 3, 1608–9.
Wu X, Li Q, Xin H, Yu A, Zhong M. Effects of berberine on the blood concentration of cyclosporin A in renal transplanted recipients: clinical and pharmacokinetic study. Eur J Clin Pharmacol (2005) 61, 567–72.
Xin HW, Wu XC, Li Q, Yu AR, Zhong MY, Liu YY. The effects of berberine on the pharmacokinetics of cyclosporin A in healthy volunteers. Methods Find Exp Clin Pharmacol (2006) 28, 25–9.
Duclos J, Goecke H. "Hierba del clavo" (Geum chiloense) interfiere niveles de ciclosporin: potencial riesgo para trasplantados. Rev Med Chil (2001) 129, 789–90.
Choi JS, Choi BC, Choi KE. Effect of quercetin on the pharmacokinetics of oral cyclosporine. Am J Health-Syst Pharm (2004) 61, 2406–9.
Prasad GVR, Wong T, Meliton G, Bhaloo S. Rhabdomyolysis due to red yeast rice (Monascus purpureus) in a renal transplant recipient. Transplantation (2002) 74, 1200–1.
Breidenbach Th, Hoffmann MW, Becker Th, Schlitt H, Klempnauer J. Drug interaction of St John’s wort with ciclosporin. Lancet (2000) 355, 1912.
Breidenbach T, Kliem V, Burg M, Radermacher J, Hoffmann MW, Klempnauer J. Profound drop of cyclosporin A whole blood trough levels caused by St John’s wort (Hypericum perforatum). Transplantation (2000) 69, 2229–30.
Barone GW, Gurley BJ, Ketel BL, Abul-Ezz SR. Herbal supplements: a potential for drug interactions in transplant recipients. Transplantation (2001) 71, 239–41.
Mai I, Kreuger H, Budde K, Johne A, Brockmoeller J, Neumayer H-H, Roots I. Hazardous pharmacokinetic interaction of Saint John’s wort (Hypericum perforatum) with the immunosuppressant cyclosporin. Int J Clin Pharmacol Ther (2000) 38, 500–2.
Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. Drug interaction between St John’s wort and cyclosporine. Ann Pharmacother (2000) 34, 1013–16.
Moschella PA-C, Jaber BL. Interaction between cyclosporine and Hypericum perforatum (St John’s wort) after organ transplantation. Am J Kidney Dis (2001) 38, 1105–7.
Turton-Weeks SM, Barone GW, Gurley BJ, Ketel BL, Lightfoot ML, Abul-Ezz SR. St John’s wort: a hidden risk for transplant patients. Prog Transplant (2001) 11, 116–20.
Karliova M, Treichel U, Malagò M, Frilling A, Gerken G, Broelsch CE. Interaction of hypericum perforatum (St John’s wort) with cyclosporin A metabolism in a patient after liver transplantation. J Hepatol (2000) 33, 853–5.
Ruschitzka F, Meier PJ, Turina M, Lüscher TF, Noll G. Acute heart transplant rejection due to Saint John’s wort. Lancet (2000) 355, 548–9.
Ahmed SM, Banner NR, Dubrey SW. Low cyclosporin-A level due to Saint-John’s-wort in heart-transplant patients. J Heart Lung Transplant (2001) 20, 795.
Bon S, Hartmann K, Kuhn M. Johanniskraut: ein enzyminducktor? Schweiz Apothekerzeitung (1999) 16, 535–6.
Alscher DM, Klotz U. Drug interaction of herbal tea containing St. John’s wort with cyclosporine. Transpl Int (2003) 16, 543–4.
Bauer S, Störmer E, Johne A, Krüger H, Budde K, Neumayer H-H, Roots I, Mai I. Alterations in cyclosporin A pharmacokinetics and metabolism during treatment with St John’s wort in renal transplant patients. Br J Clin Pharmacol (2003) 55, 203–11.
Mai I, Bauer S, Perloff ES, Johne A, Uehleke B, Frank B, Budde K, Roots I. Hyperforin content determines the magnitude of the St John’s wort–cyclosporine drug interaction. Clin Pharmacol Ther (2004) 76, 330–40.
Chen M-F, Shimada F, Kato H, Yano S, Kanaoka M. Effect of oral administration of glycyrrhizin on the pharmacokinetics of prednisolone. Endocrinol Jpn (1991) 38, 167–74.
Chen M-F, Shimada F, Kato H, Yano S, Kanaoka M. Effect of glycyrrhizin on the pharmacokinetics of prednisolone following low dosage of prednisolone hemisuccinate. Endocrinol Jpn (1990) 37, 331–41.
Ojima M, Satoh K, Gomibuchi T, Itoh N, Kin S, Fukuchi S, Miyachi Y. The inhibitory effects of glycyrrhizin and glycyrrhetinic acid on the metabolism of cortisol and prednisolone_—in vivo and in vitro studies. Nippon Naibunpi Gakkai Zasshi (1990) 66, 584–96.
Varis T, Kivistö KT, Neuvonen PJ. Grapefruit juice can increase the plasma concentrations of oral methylprednisolone. Eur J Clin Pharmacol (2000) 56, 489–93.
Hollander AA, van Rooij J, Lentjes EGWM, Arbouw F, van Bree JB, Schoemaker RC, van Es LA, van der Woude FJ, Cohen AF. The effect of grapefruit juice on cyclosporine and prednisone metabolism in transplant patients. Clin Pharmacol Ther (1995) 57, 318–24.
Westveer MK, Farquhar ML, George P, Mayes JT. Co-administration of grapefruit juice increases tacrolimus levels in liver transplant patients. Proceedings of the 15th Annual Meeting of the American Society of Transplant Physicians 1996. Abstract P-115.
Michelangelo V, Piero D, Elisa C, Enrico S, Mauro B, Pietro B. Grapefruit juice and kinetics of tacrolimus. J Am Soc Nephrol (2001) 12, 862A.
Fukatsu S, Fukudo M, Masuda S, Yano I, Katsura T, Ogura Y, Oike F, Takada Y, Inui K-I. Delayed effect of grapefruit juice on pharmacokinetics and pharmacodynamics of tacrolimus in a living-donor liver transplant recipient. Drug Metab Pharmacokinet (2006) 21, 122–5.
Egashira K, Fukuda E, Onga T, Yogi Y, Matsuya F, Koyabu N, Ohtani H, Sawada Y. Pomelo-induced increase in the blood level of tacrolimus in a renal transplant patient. Transplantation (2003) 75, 1057.
Egashira K, Ohtani H, Itoh S, Koyabu N, Tsujimoto M, Murakami H, Sawada Y. Inhibitory effects of pomelo on the metabolism of tacrolimus and the activities of CYP3A4 and P-glycoprotein. Drug Metab Dispos (2004) 32, 828–33.
Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice increases serum concentrations of atorvastatin and has no effect on pravastatin. Clin Pharmacol Ther (1999) 66, 118–27.
Ando H, Tsuruoka S, Yanagihara H, Sugimoto K, Miyata M, Yamazoe Y, Takamura T, Kaneko S, Fujimura A. Effects of grapefruit juice on the pharmacokinetics of pitavastatin and atorvastatin. Br J Clin Pharmacol (2005) 60, 494–7.
Fukazawa I, Uchida N, Uchida E, Yasuhara H. Effects of grapefruit juice on pharmacokinetics of atorvastatin and pravastatin in Japanese. Br J Clin Pharmacol (2004) 57, 448–55.
Kantola T, Kivistö KT, Neuvonen PJ. Grapefruit juice greatly increases serum concentrations of lovastatin and lovastatin acid. Clin Pharmacol Ther (1998) 63, 397–402.
Rogers JD, Zhao J, Liu L, Amin RD, Gagliano KD, Porras AG, Blum RA, Wilson MF, Stepanavage M, Vega JM. Grapefruit juice has minimal effects on plasma concentrations of lovastatin-derived 3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors. Clin Pharmacol Ther (1999) 66, 358–66.
Bailey DG, Dresser GK. Grapefruit juice-lovastatin interaction. Clin Pharmacol Ther (2000) 67, 690.
Koitabashi Y, Kumai T, Matsumoto N, Watanabe M, Sekine S, Yanagida Y, Kobayashi S. Orange juice increased the bioavailability of pravastatin, 3-hydroxy-3-methylglutaryl CoA reductase inhibitor, in rats and healthy human subjects. Life Sci (2006) 78, 2852–9.
Sorokin AV, Duncan B, Panetta R, Thompson PD. Rhabdomyolysis with pomegranate juice consumption. Am J Cardiol (2006) 98, 705–6.
Lilja JJ, Kivistö KT, Neuvonen PJ. Grapefruit juice-simvastatin interaction: effect on serum concentrations of simvastatin, simvastatin acid, and HMG-CoA reductase inhibitors. Clin Pharmacol Ther (1998) 64, 477–83.
Lilja JJ, Kivistö KT, Neuvonen PJ. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP3A4 substrate simvastatin. Clin Pharmacol Ther (2000) 68, 384–90.
Lilja JJ, Neuvonen M, Neuvonen PJ. Effects of regular consumption of grapefruit juice on the pharmacokinetics of simvastatin. Br J Clin Pharmacol (2004) 58, 56–60.
Dreier JP, Endres M. Statin-associated rhabdomyolysis triggered by grapefruit consumption. Neurology (2004) 62, 670.
Sugimoto K, Ohmori M, Tsuruoka S, Nishiki K, Kawaguchi A, Harada K, Arakawa M, Sakomoto K, Masada M, Miyamori I, Fujimura A. Different effects of St John’s wort on the pharmacokinetics of simvastatin and pravastatin. Clin Pharmacol Ther (2001) 70, 518–24.
Richter WO, Jacob BG, Schwandt P. Interaction between fibre and lovastatin. Lancet (1991) 338, 706.
Mester R, Toren P, Mizrachi I, Wolmer L, Karni N, Weizman A. Caffeine withdrawal increases lithium blood levels. Biol Psychiatry (1995) 37, 348–50.
Jefferson JW. Lithium tremor and caffeine intake: two cases of drinking less and shaking more. J Clin Psychiatry (1988) 49, 72–3.
Thomsen K, Schou M. Renal lithium excretion in man. Am J Physiol (1968) 215, 823–7.
Bikin D, Conrad KA, Mayersohn M. Lack of influence of caffeine and aspirin on lithium elimination. Clin Res (1982) 30, 249A.
Pyevich D, Bogenschutz MP. Herbal diuretics and lithium toxicity. Am J Psychiatry (2001) 158, 1329.
Kline NS. Psychopharmaceuticals: effects and side-effects. Bull WHO (1959) 21, 397–410.
Pakes GE. Phenelzine-cola headache. Am J Hosp Pharm (1979) 36, 736.
Shader RI, Greenblatt DJ. Phenelzine and the dream machine—ramblings and reflections. J Clin Psychopharmacol (1985) 5, 65.
Dawson JK, Earnshaw SM, Graham CS. Dangerous monoamine oxidase inhibitor interactions are still occurring in the 1990s. J Accid Emerg Med (1995) 12, 49–51.
Shader RI, Greenblatt DJ. MAOIs and drug interactions—a proposal for a clearinghouse. J Clin Psychopharmacol (1985) 5, A17.
Berkowitz BA, Spector S, Pool W. The interaction of caffeine, theophylline and theobromine with monoamine oxidase inhibitors. Eur J Pharmacol (1971) 16, 315–21.
Hodge JV, Nye ER, Emerson GW. Monoamine-oxidase inhibitors, broad beans, and hypertension. Lancet (1964) i, 1108.
Blomley DJ. Monoamine-oxidase inhibitors. Lancet (1964) ii, 1181–2.
McQueen EG. Interactions with monoamine oxidase inhibitors. BMJ (1975) 4, 101.
Balon R, Pohl R, Yeragani VK, Berchou R, Gershon S. Monosodium glutamate and tranylcypromine administration in healthy subjects. J Clin Psychiatry (1990) 51, 303–6.
McCabe B, Tsuang MT. Dietary consideration in MAO inhibitor regimens. J Clin Psychiatry (1982) 43, 178–81.
Pohl R, Balon R, Berchou R. Reaction to chicken nuggets in a patient taking an MAOI. Am J Psychiatry (1988) 145, 651.
Lee S, Wing YK. MAOI and monosodium glutamate interaction. J Clin Psychiatry (1991) 52, 3.
Blackwell B, Marley E, Price J, Taylor D. Hypertensive interactions between monoamine oxidase inhibitors and foodstuffs. Br J Psychiatry (1967) 113, 349–65.
Sadusk JF. The physician and the Food and Drug Administration. JAMA (1964) 190, 907–9.
Generali JA, Hogan LC, McFarlane M, Schwab S, Hartman CR. Hypertensive crisis resulting from avocados and a MAO inhibitor. Drug Intell Clin Pharm (1981) 15, 904–6.
Boulton AA, Cookson B, Paulton R. Hypertensive crisis in a patient on MAOI antidepressants following a meal of beef liver. Can Med Assoc J (1970) 102, 1394–5.
Hedberg DL, Gordon MW, Glueck BC. Six cases of hypertensive crisis in patients on tranylcypromine after eating chicken livers. Am J Psychiatry (1966) 122, 933–7.
Isaac P, Mitchell B, Grahame-Smith DG. Monoamine-oxidase inhibitors and caviar. Lancet (1977) ii, 816.
Nuessle WF, Norman FC, Miller HE. Pickled herring and tranylcypromine reaction. JAMA (1965) 192, 726–7.
Kelly D, Guirguis W, Frommer E, Mitchell-Heggs N, Sargant W. Treatment of phobic states with antidepressants. A retrospective study of 246 patients. Br J Psychiatry (1970) 116, 387–98.
Abrams JH, Schulman P, White WB. Successful treatment of a monoamine oxidase inhibitor-tyramine hypertensive emergency with intravenous labetalol. N Engl J Med (1985) 313, 52.
Mesmer RE. Don’t mix miso with MAOIs. JAMA (1987) 258, 3515.
Zetin M, Plon L, DeAntonio M. MAOI reaction with powdered protein dietary supplement. J Clin Psychiatry (1987) 48, 499.
McQueen EG. Interactions with monoamine oxidase inhibitors. BMJ (1975) 4, 101.
Comfort A. Hypertensive reaction to New Zealand prickly spinach in a woman taking phenelzine. Lancet (1981) ii, 472.
Karet FE, Dickerson JEC, Brown J, Brown MJ. Bovril and moclobemide: a novel therapeutic strategy for central autonomic failure. Lancet (1994) 344, 1263–5.
Berlin I, Zimmer R, Cournot A, Payan C, Pedarriosse AM, Puech AJ. Determination and comparison of the pressor effect of tyramine during long-term moclobemide and tranylcypromine treatment in healthy volunteers. Clin Pharmacol Ther (1989) 46, 344–51.
Bieck PR, Antonin KH. Tyramine potentiation during treatment with MAO inhibitors: brofaromine and moclobemide vs irreversible inhibitors. J Neural Transm (1989) (Suppl 28), 21–31.
Warrington SJ, Turner P, Mant TGK, Morrison P, Haywood G, Glover V, Goodwin BL, Sandler M, St John-Smith P, McClelland GR. Clinical pharmacology of moclobemide, a new reversible monoamine oxidase inhibitor. J Psychopharmacol (1991) 5, 82–91.
Korn A, Eichler HG, Fischbach R, Gasic S. Moclobemide, a new reversible MAO inhibitor – interaction with tyramine and tricyclic antidepressants in healthy volunteers and depressive patients. Psychopharmacology (Berl) (1986) 88, 153–7.
Korn A, Da Prada M, Raffesberg W, Gasic S, Eichler HG. Effect of moclobemide, a new reversible monoamine oxidase inhibitor, on absorption and pressor effect of tyramine. J Cardiovasc Pharmacol (1988) 11, 17–23.
Burgess CD, Mellsop GW. Interaction between moclobemide and oral tyramine in depressed patients. Fundam Clin Pharmacol (1989) 3, 47–52.
Audebert C, Blin O, Monjanel-Mouterde S, Auquier P, Pedarriosse AM, Dingemanse J, Durand A, Cano JP. Influence of food on the tyramine pressor effect during chronic moclobemide treatment of healthy volunteers. Eur J Clin Pharmacol (1992) 43, 507–12.
Provost J-C, Funck-Brentano C, Rovei V, D’Estanque J, Ego D, Jaillon P. Pharmacokinetic and pharmacodynamic interaction between toloxatone, a new reversible monoamine oxidase-A inhibitor, and oral tyramine in healthy subjects. Clin Pharmacol Ther (1992) 52, 384–93.
Tipton KF, Dostert P, Strolin Benedetti M, eds. Monoamine Oxidase and Disease: Pressor amines and monoamine oxidase inhibitors. London: Academic Press; 1984. p. 429–41.
Cooper AJ, Magnus RV, Rose MJ. A hypertensive syndrome with tranylcypromine medication. Lancet (1964) i, 527–9.
Anon. Hypertensive reactions to monoamine oxidase inhibitors. BMJ (1964) i, 578–9.
Da Prada M, Zürcher G, Wüthrich I, Haefely WE. On tyramine, food, beverages and the reversible MAO inhibitor moclobemide. J Neural Transm (1988) (Suppl 26), 31–56.
Price K, Smith SE. Cheese reaction and tyramine. Lancet (1971) i, 130–1.
Hutchison JC. Toxic effects of monoamine-oxidase inhibitors. Lancet (1964) ii, 151.
Sullivan EA, Shulman KI. Diet and monoamine oxidase inhibitors: a re-examination. Can J Psychiatry (1984) 29, 707–11.
McCabe BJ. Dietary tyramine and other pressor amines in MAOI regimens: a review. J Am Diet Assoc (1986) 86, 1059–64.
Brown C, Taniguchi G, Yip K. The monoamine oxidase inhibitor-tyramine interaction. J Clin Pharmacol (1989) 29, 529–32.
Gardner DM, Shulman KI, Walker SE, Tailor SAN. The making of a user friendly MAOI diet. J Clin Psychiatry (1996) 57, 99–104.
Shulman KI, Walker SE. Refining the MAOI diet: tyramine content of pizzas and soy products. J Clin Psychiatry (1999) 60, 191–3.
Shulman KI, Walker SE. Clarifying the safety of the MAOI diet and pizza: reply. J Clin Psychiatry (2000) 61, 145–6.
Marcason W. What is the bottom line for dietary guidelines when taking monoamine oxidase inhibitors? J Am Diet Assoc (2005) 105, 163.
Da Prada M, Zürcher G. Tyramine content of preserved and fermented foods or condiments of Far Eastern cuisine. Psychopharmacology (Berl) (1992) 106, S32–S34.
Sen NP. Analysis and significance of tyramine in foods. J Food Sci (1969) 34, 22–26.
Fier M. Safer use of MAOIs. Am J Psychiatry (1991) 148, 391–2.
Lippman SB, Nash K. Monoamine oxidase inhibitor update. Potential adverse food and drug interactions. Drug Safety (1990) 5, 195–204.
Fuhr U, Klittich K, Staib AH. Inhibitory effect of grapefruit juice and the active component, naringenin on CYP1A2 dependent metabolism of caffeine in man. Br J Clin Pharmacol (1993) 35, 431–6. [Title corrected by erratum].
Maish WA, Hampton EM, Whitsett TL, Shepard JD, Lovallo WR. Influence of grapefruit juice on caffeine pharmacokinetics and pharmacodynamics. Pharmacotherapy (1996) 16, 1046–52.
Abernethy DR, Todd EL. Impairment of caffeine clearance by chronic use of low-dose oestrogen-containing oral contraceptives. Eur J Clin Pharmacol (1985) 28, 425–8.
Patwardhan RV, Desmond PV, Johnson RF, Schenker S. Impaired elimination of caffeine by oral contraceptive steroids. J Lab Clin Med (1980) 95, 603–8.
Meyer FP, Canzler E, Giers H, Walther H. Langzeituntersuchung zum Einfluß von Non-Ovlon auf die Pharmakokinetik von Coffein im intraindividuellen Vergleich. Zentralbl Gynakol (1988) 110, 1449–54.
Rietveld EC, Broekman MMM, Houben JJG, Eskes TKAB, van Rossum JM. Rapid onset of an increase in caffeine residence time in young women due to oral contraceptive steroids. Eur J Clin Pharmacol (1984) 26, 371–3.
Balogh A, Klinger G, Henschel L, Börner A, Vollanth R, Kuhnz W. Influence of ethinylestradiol-containing combination oral contraceptives with gestodene or levonorgestrel on caffeine elimination. Eur J Clin Pharmacol (1995) 48, 161–6.
Pollock BG, Wylie M, Stack JA, Sorisio DA, Thompson DS, Kirshner MA, Folan MM, Condifer KA. Inhibition of caffeine metabolism by estrogen replacement therapy in postmenopausal women. J Clin Pharmacol (1999) 39, 936–40.
Brazier JL, Descotes J, Lery N, Ollagnier M, Evreux J-C. Inhibition by idrocilamide of the disposition of caffeine. Eur J Clin Pharmacol (1980) 17, 37–43.
Evreux JC, Bayere JJ, Descotes J, Lery N, Ollagnier M, Brazier JL. Les accidents neuro-psychiques de l’idrocilamide: conséquence d’une inhibition due métabolisme de la caféine? Lyon Med (1979) 241, 89–91.
Russman S, Lauterburg BH, Barguil Y, Choblet E, Cabalion P, Rentsch K, Wenk M. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens? Clin Pharmacol Ther (2005) 77, 451–4.
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther (2005) 77, 415–26.
Gelal A, Guven H, Balkan D, Artok L, Benowitz NL. Influence of menthol on caffeine disposition and pharmacodynamics in healthy female volunteers. Eur J Clin Pharmacol (2003) 59, 417–22.
Mays DC, Camisa C, Cheney P, Pacula CM, Nawoot S, Gerber N. Methoxsalen is a potent inhibitor of the metabolism of caffeine in humans. Clin Pharmacol Ther (1987) 42, 621–6.
Bendriss EK, Bechtel Y, Bendriss A, Humbert P, Paintaud G, Megnette J, Agache P, Bechtel PR. Inhibition of caffeine metabolism by 5-methoxypsoralen in patients with psoriasis. Br J Clin Pharmacol (1996) 41, 421–4.
Tantcheva-Poór I, Servera-Llaneras M, Scharffetter-Kochanek K, Fuhr U. Liver cytochrome P450 CYP1A2 is markedly inhibited by systemic but not by bath PUVA in dermatological patients. Br J Dermatol (2001) 144, 1127–32.
Staib AH, Stille W, Dietlein G, Shah PM, Harder S, Mieke S, Beer C. Interaction between quinolones and caffeine. Drugs (1987) 34 (Suppl 1), 170–4.
Carbó M, Segura J, De la Torre R, Badenas JM, Camí J. Effect of quinolones on caffeine disposition. Clin Pharmacol Ther (1989) 45, 234–40.
Harder S, Staib AH, Beer C, Papenburg A, Stille W, Shah PM. 4-Quinolones inhibit biotransformation of caffeine. Eur J Clin Pharmacol (1988) 35, 651–6.
Stille W, Harder S, Mieke S, Beer C, Shah PM, Frech K, Staib AH. Decrease of caffeine elimination in man during co-administration of 4-quinolones. J Antimicrob Chemother (1987) 20, 729–34.
Healy DP, Schoenle JR, Stotka J, Polk RE. Lack of interaction between lomefloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother (1991) 35, 660–4.
Peloquin CA, Nix DE, Sedman AJ, Wilton JH, Toothaker RD, Harrison NJ, Schentag JJ. Pharmacokinetics and clinical effects of caffeine alone and in combination with oral enoxacin. Rev Infect Dis (1989) II (Suppl 5), S1095.
Healy DP, Polk RE, Kanawati L, Rock DT, Mooney ML. Interaction between oral ciprofloxacin and caffeine in normal volunteers. Antimicrob Agents Chemother (1989) 33, 474–8.
Nicolau DP, Nightingale CH, Tessier PR, Fu Q, Xuan D-w, Esguerra EM, Quintiliani R. The effect of fleroxacin and ciprofloxacin on the pharmacokinetics of multiple dose caffeine. Drugs (1995) 49 (Suppl 2), 357–9.
LeBel M, Teng R, Dogolo LC, Willavize S, Friedman HL, Vincent J. The influence of steady-state trovafloxacin on the steady-state pharmacokinetics of caffeine in healthy subjects. Pharm Res (1996) 13 (Suppl 9), S434.
Randinitis EJ, Koup JR, Rausch G, Vassos AB. Effect of (CLX) administration on the single-dose pharmacokinetics of theophylline and caffeine. Intersci Conf Antimicrob Agents Chemother (1998) 38, 6.
Cesana M, Broccali G, Imbimbo BP, Crema A. Effect of single doses of rufloxacin on the disposition of theophylline and caffeine after single administration. Int J Clin Pharmacol Ther Toxicol (1991) 29, 133–8.
Kinzig-Schippers M, Fuhr U, Zaigler M, Dammeyer J, Rüsing G, Labedzki A, Bulitta J, Sörgel F. Interaction of pefloxacin and enoxacin with the human cytochrome P450 enzyme CYP1A2. Clin Pharmacol Ther (1999) 65, 262–74.
Kim M-Y, Nightingale CH, Nicolau DP. Influence of sex on the pharmacokinetic interaction of fleroxacin and ciprofloxacin with caffeine. Clin Pharmacokinet (2003), 42, 985–96.
Fuhr U, Wolff T, Harder S, Schymanski P, Staib AH. Quinolone inhibition of cytochrome P450-dependent caffeine metabolism in human liver microsomes. Drug Metab Dispos (1990) 18, 1005–10.
Barnett G, Segura J, de la Torre R, Carbó M. Pharmacokinetic determination of relative potency of quinolone inhibition of caffeine disposition. Eur J Clin Pharmacol (1990) 39, 63–9.
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther (2004) 76, 428–40.
Saruwatari J, Nakagawa K, Shindo J, Nachi S, Echizen H, Ishizaki T. The in-vivo effects of sho-saiko-to, a traditional Chinese herbal medicine, on two cytochrome P450 enzymes (1A2 and 3A) and xanthine oxidase in man. J Pharm Pharmacol (2003) 55, 1553–9.
Wenk M, Todesco L, Krähenbühl S. Effect of St John’s wort on the activities of CYP1A2, CYP3A4, CYP2D6, N-acetyltransferase 2, and xanthine oxidase in healthy males and females. Br J Clin Pharmacol (2004) 57, 494–9.
Bapiro TE, Sayi J, Hasler JA, Jande M, Rimoy G, Masselle A, Masimirembwa CM. Artemisinin and thiabendazole are potent inhibitors of cytochrome P450 1A2 (CYP1A2) activity in humans. Eur J Clin Pharmacol (2005) 61, 755–61.
Amchin J, Zarycranski W, Taylor KP, Albano D, Klockowski PM. Effect of venlafaxine on CYP1A2-dependent pharmacokinetics and metabolism of caffeine. J Clin Pharmacol (1999) 39, 252–9.
Nawoot S, Wong D, Mays DC, Gerber N. Inhibition of caffeine elimination by verapamil. Clin Pharmacol Ther (1988) 43, 148.
Karim A, Burns T, Wearley L, Streicher J, Palmer M. Food-induced changes in theophylline absorption from controlled-release formulations. Part I. Substantial increased and decreased absorption with Uniphyl tablets and Theo-Dur Sprinkle. Clin Pharmacol Ther (1985) 38, 77–83.
Lohmann A, Dingler E, Sommer W. Influence of food on the bioavailability of theophylline from a sustained-release theophylline preparation. Arzneimittelforschung (1991) 41, 732–4.
Vaughan L, Milavetz G, Hill M, Weinberger M, Hendeles L. Food-induced dose-dumping of Theo-24, a ‘once-daily’ slow-release theophylline product. Drug Intell Clin Pharm (1984) 18, 510.
Johansson Ö, Lindberg T, Melander A, Wåhlin-Boll E. Different effects of different nutrients on theophylline absorption in man. Drug Nutr Interact (1985) 3, 205–11.
Sips AP, Edelbroek PM, Kulstad S, de Wolff FA, Dijkman JH. Food does not effect bioavailability of theophylline from Theolin Retard. Eur J Clin Pharmacol (1984) 26, 405–7.
Steffensen G, Pedersen S. Food induced changes in theophylline absorption from a once-a-day theophylline product. Br J Clin Pharmacol (1986) 22, 571–7.
Ürmös I, Grézal G, Balogh Nemes K, Szállási T, Drabant S, Csörgo M, Klebovich I. Food interaction study of a new theophylline (Egifilin) 200 and 400 mg retard tablet in healthy volunteers. Int J Clin Pharmacol Ther (1997) 35, 65–70.
González MA, Straughn AB. Effect of meals and dosage-form modification on theophylline bioavailability from a 24-hour sustained-release delivery system. Clin Ther (1994) 16, 804–14.
Thebault JJ, Aiache JM, Mazoyer F, Cardot JM. The influence of food on the bioavailability of a slow release theophylline preparation. Clin Pharmacokinet (1987) 13, 267–72.
Lefebvre RA, Belpaire FM, Bogaert MG. Influence of food on steady state serum concentrations of theophylline from two controlled-release preparations. Int J Clin Pharmacol Ther Toxicol (1988) 26, 375–9.
Fassihi AR, Dowse R, Robertson SSD. Effect of dietary cellulose on the absorption and bioavailability of theophylline. Int J Pharmaceutics (1989) 50, 79–82.
Kappas A, Anderson KE, Conney AH, Alvares AP. Influence of dietary protein and carbohydrate on antipyrine and theophylline metabolism in man. Clin Pharmacol Ther (1976) 20, 643–53.
Feldman CH, Hutchinson VE, Pippenger CE, Blumenfeld TA, Feldman BR, Davis WJ. Effect of dietary protein and carbohydrate on theophylline metabolism in children. Pediatrics (1980) 66, 956–62.
Thompson PJ, Skypala I, Dawson S, McAllister WAC, Turner Warwick M. The effect of diet upon serum concentrations of theophylline. Br J Clin Pharmacol (1983) 16, 267–70.
Anderson KE, McCleery RB, Vesell ES, Vickers FF, Kappas A. Diet and cimetidine induce comparable changes in theophylline metabolism in normal subjects. Hepatology (1991) 13, 941–6.
Bouraoui A, Toumi A, Bouchahcha S, Boukef K, Brazier JL. Influence de l’alimentation épicée et piquante sur l’absorption de la théophylline. Therapie (1986) 41, 467–71.
Gal P, Layson R. Interference with oral theophylline absorption by continuous nasogastric feedings. Ther Drug Monit (1986) 8, 421–3.
Bhargava VO, Schaaf LJ, Berlinger WG, Jungnickel PW. Effect of an enteral nutrient formula on sustained-release theophylline absorption. Ther Drug Monit (1989) 11, 515–19.
Plezia PM, Thornley SM, Kramer TH, Armstrong EP. The influence of enteral feedings on sustained-release theophylline absorption. Pharmacotherapy (1990) 10, 356–61.
Ziegenbein RC. Theophylline clearance increase from increased amino acid in a CPN regimen. Drug Intell Clin Pharm (1987) 21, 220–1.
Cuddy PG, Bealer JF, Lyman EL, Pemberton LB. Theophylline disposition following parenteral feeding of malnourished patients. Ann Pharmacother (1993) 27, 846–51.
Pantuck EJ, Pantuck CB, Garland WA, Min BH, Wattenberg LW, Anderson KE, Kappas A, Conney AH. Stimulatory effect of Brussels sprouts and cabbage on human drug metabolism. Clin Pharmacol Ther (1979) 25, 88–95.
Kleman MI, Overvik E, Poellinger L, Gustafsson JA. Induction of cytochrome P4501A isoenzymes by heterocyclic amines and other food-derived compounds. Princess Takamatsu Symp (1995) 23, 163–71.
Kappas A, Alvares AP, Anderson KE, Pantuck EJ, Pantuck CB, Chang R, Conney AH. Effect of charcoal-broiled beef on antipyrine and theophylline metabolism. Clin Pharmacol Ther (1979) 23, 445–50.
Peng W-X, Li H-D, Zhou H-H. Effect of daidzein on CYP1A2 activity and pharmacokinetics of theophylline in healthy volunteers. Eur J Clin Pharmacol (2002) 59, 237–41.
Fuhr U, Maier A, Keller A, Steinijans VW, Sauter R, Staib AH. Lacking effect of grapefruit juice on theophylline pharmacokinetics. Int J Clin Pharmacol Ther (1995) 33, 311–14.
Stewart DE. Venlafaxine and sour date nut. Am J Psychiatry (2004) 161, 1129–30.
DeSilva KE, Le Flore DB, Marston BJ, Rimland D. Serotonin syndrome in HIV-infected individuals receiving antiretroviral therapy and fluoxetine. AIDS (2001) 15, 1281–5.
Hori H, Yoshimura R, Ueda N, Eto S, Shinkai K, Sakata S, Ohmori O, Terao T, Nakamura J. Grapefruit juice-fluvoxamine interaction. Is it risky or not? J Clin Psychopharmacol (2003) 23, 422–4.
Wiens A. How does grapefruit juice affect psychotropic medications? J Psychiatry Neurosci (2000) 25, 198.
Lee AJ, Chan WK, Harralson AF, Buffum J, Bui B-CC. The effects of grapefruit juice on sertraline metabolism: an in vitro and in vivo study. Clin Ther (1999) 21, 1890–9.
Callaway JC, Grob CS. Ayahuasca preparations and serotonin reuptake inhibitors: a potential combination for severe adverse interactions. J Psychoactive Drugs (1998) 30, 367–9.
Yamada K, Yagi G, Kanba S. Effectiveness of Gorei-san (TJ-17) for treatment of SSRI-induced nausea and dyspepsia: preliminary observations. Clin Neuropharmacol (2003) 26, 112–14.
Gordon JB. SSRIs and St. John’s wort: possible toxicity? Am Fam Physician (1998) 57, 950–3.
Lantz MS, Buchalter E, Giambanco V. St. John’s wort and antidepressant drug interactions in the elderly. J Geriatr Psychiatry Neurol (1999) 12, 7–10.
Barbenel DM, Yusufi B, O’Shea D, Bench CJ. Mania in a patient receiving testosterone replacement post-orchidectomy taking St John’s wort and sertraline. J Psychopharmacol (2000) 14, 84–6.
Izzo AA. Drug interactions with St. John’s wort (Hypericum perforatum): a review of the clinical evidence. Int J Clin Pharmacol Ther (2004) 42, 139–48.
Demott K. St. John’s wort tied to serotonin syndrome. Clin Psychiatry News (1998) 26, 28.
Galluzzi S, Zanetti O, Binetti G, Trabucchi M, Frisoni GB. Coma in a patient with Alzheimer’s disease taking low dose trazodone and ginkgo biloba. J Neurol Neurosurg Psychiatry (2000) 68, 679–80.
Stewart DE. High-fiber diet and serum tricyclic antidepressant levels. J Clin Psychopharmacol (1992) 12, 438–40.
Abernethy DR, Divoll M, Greenblatt DJ, Shader RI. Imipramine pharmacokinetics and absolute bioavailability: effect of food. Clin Res (1983) 31, 626A.
Liedholm H, Lidén A. Food intake and the presystemic metabolism of single doses of amitriptyline and nortriptyline. Fundam Clin Pharmacol (1998) 12, 636–42.
Vandel P, Regina W, Reix I, Vandel S, Sechter D, Bizouard P. Faut-il contre-indiquer le jus de pamplemousse? Une approche en psychiatrie. [Grapefruit juice as a contraindication? An approach in psychiatry]. Encephale (1999) 25, 67–71.
Domingo JL, Gomez M, Llobet JM, Richart C. Effect of ascorbic acid on gastrointestinal aluminium absorption. Lancet (1991) 338, 1467.
Domingo JL, Gomez M, Llobet JM, Corbella J. Influence of some dietary constituents on aluminum absorption and retention in rats. Kidney Int (1991) 39, 598–601.
Bakir AA, Hryhorczuk DO, Berman E, Dunea G. Acute fatal hyperaluminemic encephalopathy in undialyzed and recently dialyzed uremic patients. Trans Am Soc Artif Intern Organs (1986) 32, 171–6.
Bakir AA, Hryhorczuk DO, Ahmed S, Hessl SM, Levy PS, Spengler R, Dunea G. Hyperaluminemia in renal failure: the influence of age and citrate intake. Clin Nephrol (1989) 31, 40–4.
Kirschbaum HB, Schoolwerth AC. Acute aluminum toxicity associated with oral citrate and aluminum-containing antacids. Am J Med Sci (1989) 297, 9–11.
Rudy D, Sica DA, Comstock T, Davis J, Savory J, Schoolwerth AC. Aluminum-citrate interaction in end-stage renal disease. Int J Artif Organs (1991) 14, 625–9.
Main J, Ward MK. Potentiation of aluminium absorption by effervescent analgesic tablets in a haemodialysis patient. BMJ (1992) 304, 1686.
Coburn JW, Mischel MG, Goodman WG, Salusky IB. Calcium citrate markedly enhances aluminum absorption from aluminium hydroxide. Am J Kidney Dis (1991) 17, 708–11.
Walker JA, Sherman RA, Cody RP. The effect of oral bases on enteral aluminum absorption. Arch Intern Med (1990) 150, 2037–9.
Slanina P, Frech W, Ekström L-G, Lööf L, Slorach S, Cedergren A. Dietary citric acid enhances absorption of aluminum in antacids. Clin Chem (1986) 32, 539–41.
Weberg R, Berstad A. Gastrointestinal absorption of aluminium from single doses of aluminium containing antacids in man. Eur J Clin Invest (1986) 16, 428–32.
Fairweather-Tait S, Hickson K, McGaw B, Reid M. Orange juice enhances aluminium absorption from antacid preparation. Eur J Clin Nutr (1994) 48, 71–3.
Dorhout Mees EJ, Basçi A. Citric acid in calcium effervescent tablets may favour aluminium intoxication. Nephron (1991) 59, 322.
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Carrier J, Khan IA, Edwards DJ, Shah A. In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto. Clin Pharmacol Ther (2004) 76, 428–40.
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther (2005) 77, 415–26.
Holman CP, Bell AFJ. A trial of evening primrose oil in the treatment of chronic schizophrenia. J Orthomol Psychiatry (1983) 12, 302–4.
Vaddadi KS. The use of gamma-linolenic acid and linoleic acid to differentiate between temporal lobe epilepsy and schizophrenia. Prostaglandins Med (1981) 6, 375–9.
Vaddadi KS, Courtney P, Gilleard CJ, Manku MS, Horrobin DF. A double-blind trial of essential fatty acid supplementation in patients with tardive dyskinesia. Psychiatry Res (1989) 27, 313–23.
Vaddadi KS, Horrobin DF. Weight loss produced by evening primrose oil administration in normal and schizophrenic individuals. IRCS Med Sci (1979) 7, 52.
Markowitz JS, DeVane CL, Chavin KD, Taylor RM, Ruan Y, Donovan JL. Effects of garlic (Allium sativum L.) supplementation on cytochrome P450 2D6 and 3A4 activity in healthy volunteers. Clin Pharmacol Ther (2003) 74, 170–7.
Donovan JL, DeVane CL, Chavin KD, Taylor RM, Markowitz JS. Siberian ginseng (Eleutheroccus [sic] senticosus) effects on CYP2D6 and CYP3A4 activity in normal volunteers. Drug Metab Dispos (2003) 31, 519–22.
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther (2005) 77, 415–26.
Muñoz LM, Lönnerdal B, Keen CL, Dewey KG. Coffee consumption as a factor in iron deficiency anemia among pregnant women and their infants in Costa Rica. Am J Clin Nutr (1988) 48, 645–51.
Merhav H, Amitai Y, Palti H, Godfrey S. Tea drinking and microcytic anemia in infants. Am J Clin Nutr (1985) 41, 1210–13.
Mahlknecht U, Weidmann E, Seipelt G. Black tea delays recovery from iron-deficiency anaemia. Haematologica (2001) 86, 559.
Koren G, Boichis H, Keren G. Effects of tea on the absorption of pharmacological doses of an oral iron preparation. Isr J Med Sci (1982) 18, 547.
Russman S, Lauterburg BH, Barguil Y, Choblet E, Cabalion P, Rentsch K, Wenk M. Traditional aqueous kava extracts inhibit cytochrome P450 1A2 in humans: protective effect against environmental carcinogens? Clin Pharmacol Ther (2005) 77, 451–4.
Gurley BJ, Gardner SF, Hubbard MA, Williams DK, Gentry WB, Khan IA, Shah A. In vivo effects of goldenseal, kava kava, black cohosh, and valerian on human cytochrome P450 1A2, 2D6, 2E1, and 3A4/5 phenotypes. Clin Pharmacol Ther (2005) 77, 415–26.
Härtter S, Nordmark A, Rose D-M, Bertilsson L, Tybring G, Laine K. Effects of caffeine intake on the pharmacokinetics of melatonin, a probe drug for CYP1A2 activity. Br J Clin Pharmacol (2003) 56, 679–682.
Härtter S, Korhonen T, Lundgren S, Rane A, Tolonen A, Turpeinen M, Laine K. Effect of caffeine intake 12 or 24 hours prior to melatonin intake and CYP1A2*1F polymorphism on CYP1A2 phenotyping by melatonin. Basic Clin Pharmacol Toxicol (2006) 99, 300–4.
Ursing C, Wikner J, Brismar K, Röjdmark S. Caffeine raises the serum melatonin level in healthy subjects: an indication of melatonin metabolism by cytochrome P450 (CYP)1A2. J Endocrinol Invest (2003) 26, 403–6.
Jetter A, Kinzig-Schippers M, Walchner-Bonjean M, Hering U, Bulitta J, Schreiner P, Sörgel F, Fuhr U. Effects of grapefruit juice on the pharmacokinetics of sildenafil. Clin Pharmacol Ther (2002) 71, 21–9.
Haller CA, Jacob P, Benowitz NL. Enhanced stimulant and metabolic effects of combined ephedrine and caffeine. Clin Pharmacol Ther (2004) 75, 259–73.
Astrup A, Breum L, Toubro S, Hein P, Quaade F. The effect and safety of an ephedrine/caffeine compound compared to ephedrine, caffeine and placebo in obese subjects on an energy restricted diet. A double blind trial. Int J Obes Relat Metab Disord (1992) 16, 269–77.
Haller CA, Benowitz NL. Adverse cardiovascular and central nervous system events associated with dietary supplements containing ephedra alkaloids. N Engl J Med (2000) 343, 1833–8.
Shekelle PG, Hardy ML, Morton SC, Maglione M, Mojica WA, Suttorp MJ, Rhodes SL, Jungvig L, Gagné J. Efficacy and safety of ephedra and ephedrine for weight loss and athletic performance: a meta-analysis. JAMA (2003) 280, 1537–45.
Tormey WP, Bruzzi A. Acute psychosis due to the interaction of legal compounds – ephedra alkaloids in ‘Vigueur Fit’ tablets, caffeine in ‘Red Bull’ and alcohol. Med Sci Law (2001) 41, 331–6.
Lake CR, Zaloga G, Bray J, Rosenberg D, Chernow B. Transient hypertension after two phenylpropanolamine diet aids and the effects of caffeine: a placebo-controlled follow-up study. Am J Med (1989) 86, 427–32.
Lake CR, Rosenberg DB, Gallant S, Zaloga G, Chernow B. Phenylpropanolamine increases plasma caffeine levels. Clin Pharmacol Ther (1990) 47, 675–85.
Brown NJ, Ryder D, Branch RA. A pharmacodynamic interaction between caffeine and phenylpropanolamine. Clin Pharmacol Ther (1991) 50, 363–71.
Lake CR. Manic psychosis after coffee and phenylpropanolamine. Biol Psychiatry (1991) 30, 401–4.
Lake CR, Gallant S, Masson E, Miller P. Adverse drug effects attributed to phenylpropanolamine: a review of 142 case reports. Am J Med (1990) 89, 195– 208.
Puig L. Pharmacodynamic interaction with phototoxic plants during PUVA therapy. Br J Dermatol (1997) 136, 973–4.
Boffa MJ, Gilmour E, Ead RD. Celery soup causing severe phototoxicity during PUVA therapy. Br J Dermatol (1996) 135, 330–45.
Johne A, Perloff ES, Bauer S, Schmider J, Mai I, Brockmöller J, Roots I. Impact of cytochrome P-450 inhibition by cimetidine and induction by carbamazepine on the kinetics of hypericin and pseudohypericin in healthy volunteers. Eur J Clin Pharmacol (2004) 60, 617–22.
Lilja JJ, Laitinen K, Neuvonen PJ. Effects of grapefruit juice on the absorption of levothyroxine. Br J Clin Pharmacol (2005) 60, 337–41.
Booth NL, Nikolic D, van Breemen RB, Geller SE, Banuvar S, Shulman LP, Farnsworth NR. Confusion regarding anticoagulant coumarins in dietary supplements. Clin Pharmacol Ther (2004) 76, 511–16.
Simth L, Ernst E, Ewings P, Myers P, Smith C. Co-ingestion of herbal medicines and warfarin. Br J Gen Pract (2004) 54, 439–41.
Wong RSM, Cheng G, Chan TYK. Use of herbal medicines by patients receiving warfarin. Drug Safety (2003) 26, 585–8.
Lambert JP, Cormier A. Potential interaction between warfarin and boldo-fenugreek. Pharmacotherapy (2001) 21, 509–12.
Segal R, Pilote L. Warfarin interaction with Matricaria chamomilla. Can Med Assoc J (2006) 174, 1281–2.
Yue, Q-Y, Jansson K. Herbal drug Curbicin and anticoagulant effect with and without warfarin: possibly related to the vitamin E component. J Am Geriatr Soc (2001) 49, 838.
Yu CM, Chan JCN, Sanderson JE. Chinese herbs and warfarin potentiation by ‘Danshen’. J Intern Med (1997) 241, 337–9.
Izzat MB, Yim APC, El-Zufari MH. A taste of Chinese medicine. Ann Thorac Surg (1998) 66, 941–2.
Lo ACT, Chan K, Yeung JHK, Woo KS. The effects of Danshen (Salvia miltiorrhiza) on pharmacokinetics and dynamics of warfarin in rats. Eur J Drug Metab Pharmacokinet (1992) 17, 257–62.
Page RL, Lawrence JD. Potentiation of warfarin by dong quai. Pharmacotherapy (1999) 19, 870–6.
Ellis GR, Stephens MR. Untitled report. BMJ (1999) 319, 650.
Sunter W. Warfarin and garlic. Pharm J (1991) 246, 722.
Macan H, Uykimpang R, Alconcel M, Takasu J, Razon R, Amagase H, Niihara Y. Aged garlic extract may be safe for patients on warfarin therapy. J Nutr (2006) 136 (3 Suppl), 793S–795S.
Shalansky S, Neall E, Lo M, Abd-Elmessih E, Vickars L, Lynd L. The impact of complementary and alternative medicine use on warfarin-related adverse outcomes. Pharmacotherapy (2002) 22, 1345.
German K, Kumar U, Blackford HN. Garlic and the risk of TURP bleeding. Br J Urol (1995) 76, 518.
Rose KD, Croissant PD, Parliament CF, Levin MP. Spontaneous spinal epidural hematoma with associated platelet dysfunction from excessive garlic ingestion: a case report. Neurosurgery (1990) 26, 880–2.
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 59, 425–32.
Krüth P, Brosi E, Fux R, Mörike K, Gleiter CH. Ginger-associated overanticoagulation by phenprocoumon. Ann Pharmacother (2004) 38, 257–60.
Lesho EP, Saullo L, Udvari-Nagy S. A 76-year-old woman with erratic anticoagulation. Cleve Clin J Med (2004) 71, 651–6 .
Argento A, Tiraferri E, Marzaloni M. Anticoagulanti orali e piante medicinali. Una interazione emergente. Ann Ital Med Int (2000) 15, 139–43.
Braun L. Herb-drug interaction guide. Aust Fam Physician (2001) 30, 473–6.
Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother (2000) 34, 1478–82.
Engelsen J, Nielsen JD, Winther K. Effect of coenzyme Q 10 and ginkgo biloba on warfarin dosage in stable, long-term warfarin treated outpatients. A randomised, double blind, placebo-crossover trial. Thromb Haemost (2002) 87, 1075–6.
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of ginkgo and ginger on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2005) 59, 425–32.
Lai C-F, Chang C-C, Fu C-H, Chen C-M. Evaluation of the interaction between warfarin and ginkgo biloba extract. Pharmacotherapy (2002) 22, 1326.
Matthews MK. Association of Ginkgo biloba with intracerebral hemorrhage. Neurology (1998) 50, 1933.
Vaes LPJ, Chyka PA. Interactions of warfarin with garlic, ginger, ginkgo, or ginseng: nature of the evidence. Ann Pharmacother (2000) 34, 1478–82.
Mohutsky MA, Anderson GA, Miller JW, Elmer GW. Ginkgo biloba: evaluation of CYP2C9 drug interactions in vitro and in vivo. Am J Ther (2006) 13, 24–31.
Plotnikoff GA, McKenna D, Watanabe K, Blumenthal M. Ann Intern Med (2004) 141, 893–4.
Zhu M, Chan KW, Ng LS, Chang Q, Chang S, Li RC. Possible influences of ginseng on the pharmacokinetics and pharmacodynamics of warfarin in rats. J Pharm Pharmacol (1999) 51, 175–80.
Hopkins MP, Androff L, Benninghoff AS. Ginseng face cream and unexplained vaginal bleeding. Am J Obstet Gynecol (1988) 159, 1121–2.
Greenspan EM. Ginseng and vaginal bleeding. JAMA (1983) 249, 2018.
Kuo S-C, Teng C-M, Leed J-C, Ko F-N, Chen S-C, Wu T-S. Antiplatelet components in Panax ginseng. Planta Med (1990) 56, 164–7.
Janetzky K, Morreale AP. Probable interaction between warfarin and ginseng. Am J Health-Syst Pharm (1997) 54, 692–3.
Rosado MF. Thrombosis of a prosthetic aortic valve disclosing a hazardous interaction between warfarin and a commercial ginseng product. Cardiology (2003) 99, 111.
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 57, 592–99.
Yuan C-S, Wei G, Dey L, Karrison T, Nahlik L, Maleckar S, Kasza K, Ang-Lee M, Moss J. Brief communication: American ginseng reduces warfarin’s effect in healthy patients. Ann Intern Med (2004) 141, 23–27.
Chiffoleau A, Huguenin H, Veyrac G, Argaiz V, Dupe D, Kayser M, Bourin M, Jolliet P. Interaction entre mélilot et acénocoumarol ? (mélilot-ruscus aculeatus). Therapie (2001) 56, 321–7.
Hogan RP. Hemorrhagic diathesis caused by drinking an herbal tea. JAMA (1983) 249, 2679–80.
Wong ALN, Chan TYK. Interaction between warfarin and the herbal product quilinggao. Ann Pharmacother (2003) 37, 836–8.
Maurer A, Johne A, Bauer S, Brockmöller J, Donath F, Roots I, Langheinrich M, Hübner W-D. Interaction of St John’s wort extract with phenprocoumon. Eur J Clin Pharmacol (1999) 55, A22.
Bon S, Hartmann, Kuhn M. Johanniskraut: Ein Enzyminduktor? Schweiz Apothekerzeitung (1999) 16, 535–6.
Jiang X, Williams KM, Liauw WS, Ammit AJ, Roufogalis BD, Duke CC, Day RO, McLachlan AJ. Effect of St John’s wort and ginseng on the pharmacokinetics and pharmacodynamics of warfarin in healthy subjects. Br J Clin Pharmacol (2004) 57, 592–9.
Yue Q-Y, Bergquist C, Gerdén B. Safety of St John’s wort (Hypericum perforatum). Lancet (2000) 355, 576–7.
Bransgrove LL. Interaction between warfarin and a vitamin K-containing nutritional supplement: a case report. J Herb Pharmacother (2001) 1, 85–89.
Carr ME, Klotz J, Bergeron M. Coumadin resistance and the vitamin supplement “Noni”. Am J Hematol (2004) 77, 103–4.


